{"answers":[{"exact_answer":[["abc","def"],["abc","def"]],"ideal_answer":"pseudo ideal answer","id":"5133b9455274a5fb0700000c","body":"What is the most prominent sequence consensus for the polyadenylation site?","type":"list","documents":[],"snippets":[],"concepts":["http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field\u003duid\u0026exact\u003dFind+Exact+Term\u0026term\u003dD016384","http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field\u003duid\u0026exact\u003dFind+Exact+Term\u0026term\u003dD032921","http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field\u003duid\u0026exact\u003dFind+Exact+Term\u0026term\u003dD026723","http://amigo.geneontology.org/cgi-bin/amigo/term_details?term\u003dGO:0001147","http://amigo.geneontology.org/cgi-bin/amigo/term_details?term\u003dGO:0043631","http://amigo.geneontology.org/cgi-bin/amigo/term_details?term\u003dGO:0006378","http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field\u003duid\u0026exact\u003dFind+Exact+Term\u0026term\u003dD016324","http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field\u003duid\u0026exact\u003dFind+Exact+Term\u0026term\u003dD020539","http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field\u003duid\u0026exact\u003dFind+Exact+Term\u0026term\u003dD039221","http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field\u003duid\u0026exact\u003dFind+Exact+Term\u0026term\u003dD003245","http://www.uniprot.org/uniprot/IRF8_HUMAN","http://www.uniprot.org/uniprot/IRF8_MOUSE","http://www.uniprot.org/uniprot/IRF8_CHICK","http://www.uniprot.org/uniprot/PABP_DROME","http://amigo.geneontology.org/cgi-bin/amigo/term_details?term\u003dGO:0008143","http://amigo.geneontology.org/cgi-bin/amigo/term_details?term\u003dGO:0004652","http://www.biosemantics.org/jochem#4249823","http://www.biosemantics.org/jochem#4274011","http://www.biosemantics.org/jochem#4278087","http://www.biosemantics.org/jochem#4257764","http://www.biosemantics.org/jochem#4006009","http://www.biosemantics.org/jochem#4013679","http://www.biosemantics.org/jochem#4002540","http://www.biosemantics.org/jochem#4259935","http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field\u003duid\u0026exact\u003dFind+Exact+Term\u0026term\u003dD008618","http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field\u003duid\u0026exact\u003dFind+Exact+Term\u0026term\u003dD011061","http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field\u003duid\u0026exact\u003dFind+Exact+Term\u0026term\u003dD012333","http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field\u003duid\u0026exact\u003dFind+Exact+Term\u0026term\u003dD011062","http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field\u003duid\u0026exact\u003dFind+Exact+Term\u0026term\u003dD008393","http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field\u003duid\u0026exact\u003dFind+Exact+Term\u0026term\u003dD020134","http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field\u003duid\u0026exact\u003dFind+Exact+Term\u0026term\u003dD001665"],"triples":[{"s":"http://linkedlifedata.com/resource/umls/id/C0079160","p":"http://linkedlifedata.com/resource/umls/prefMetaMap"},{"p":"http://www.w3.org/1999/02/22-rdf-syntax-ns#type","o":"http://www.w3.org/2008/05/skos-xl#Label"},{"p":"http://www.w3.org/2004/02/skos/core#notation","o":"D016384"},{"p":"http://www.w3.org/2004/02/skos/core#note","o":"MeSH"},{"p":"http://www.w3.org/2008/05/skos-xl#literalForm","o":"Consensus Sequence"},{"s":"http://linkedlifedata.com/resource/umls/id/C0079160","p":"http://www.w3.org/2008/05/skos-xl#prefLabel"},{"s":"http://linkedlifedata.com/resource/umls/id/C0079160","p":"http://linkedlifedata.com/resource/umls/altMetaMap"},{"p":"http://www.w3.org/1999/02/22-rdf-syntax-ns#type","o":"http://www.w3.org/2008/05/skos-xl#Label"},{"p":"http://www.w3.org/2004/02/skos/core#notation","o":"D016384"},{"p":"http://www.w3.org/2004/02/skos/core#note","o":"MeSH"},{"s":"http://linkedlifedata.com/resource/umls/id/C0079160","p":"http://www.w3.org/2008/05/skos-xl#altLabel"},{"p":"http://www.w3.org/2008/05/skos-xl#literalForm","o":"Consensus Sequences"},{"p":"http://www.w3.org/1999/02/22-rdf-syntax-ns#type","o":"http://www.w3.org/2008/05/skos-xl#Label"},{"p":"http://www.w3.org/2004/02/skos/core#notation","o":"D016384"},{"p":"http://www.w3.org/2004/02/skos/core#note","o":"MeSH"},{"s":"http://linkedlifedata.com/resource/umls/id/C0079160","p":"http://www.w3.org/2008/05/skos-xl#altLabel"},{"p":"http://www.w3.org/2008/05/skos-xl#literalForm","o":"Sequences, Consensus"},{"s":"http://linkedlifedata.com/resource/umls/id/C0079160","p":"http://linkedlifedata.com/resource/umls/altMetaMap"},{"p":"http://www.w3.org/1999/02/22-rdf-syntax-ns#type","o":"http://www.w3.org/2008/05/skos-xl#Label"},{"p":"http://www.w3.org/2004/02/skos/core#notation","o":"C40982"},{"p":"http://www.w3.org/2004/02/skos/core#note","o":"NCI Thesaurus"},{"s":"http://linkedlifedata.com/resource/umls/id/C0079160","p":"http://www.w3.org/2008/05/skos-xl#altLabel"},{"p":"http://www.w3.org/2008/05/skos-xl#literalForm","o":"Consensus Sequence"}]},{"exact_answer":[["abc","def"],["abc","def"]],"ideal_answer":"pseudo ideal answer","id":"513f45abbee46bd34c000013","body":"Which extra thyroid tissues have thyrotropin (TSH) receptors?","type":"list","documents":["http://www.ncbi.nlm.nih.gov/pubmed/11399468","http://www.ncbi.nlm.nih.gov/pubmed/8320423","http://www.ncbi.nlm.nih.gov/pubmed/19553036","http://www.ncbi.nlm.nih.gov/pubmed/7794253","http://www.ncbi.nlm.nih.gov/pubmed/12515285","http://www.ncbi.nlm.nih.gov/pubmed/18400223","http://www.ncbi.nlm.nih.gov/pubmed/14669949"],"snippets":[],"concepts":["http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field\u003duid\u0026exact\u003dFind+Exact+Term\u0026term\u003dD011989","http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field\u003duid\u0026exact\u003dFind+Exact+Term\u0026term\u003dD011988","http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field\u003duid\u0026exact\u003dFind+Exact+Term\u0026term\u003dD013972","http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field\u003duid\u0026exact\u003dFind+Exact+Term\u0026term\u003dD018025","http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field\u003duid\u0026exact\u003dFind+Exact+Term\u0026term\u003dD014024","http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field\u003duid\u0026exact\u003dFind+Exact+Term\u0026term\u003dD037021","http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field\u003duid\u0026exact\u003dFind+Exact+Term\u0026term\u003dD037042","http://www.uniprot.org/uniprot/TSHR_PIG","http://www.uniprot.org/uniprot/TSHR_RAT","http://www.uniprot.org/uniprot/TSHR_SHEEP","http://www.uniprot.org/uniprot/TSHR_BOVIN","http://www.uniprot.org/uniprot/TSHR_CANFA","http://www.uniprot.org/uniprot/TSHR_MOUSE","http://www.uniprot.org/uniprot/TSHR_FELCA","http://www.uniprot.org/uniprot/TSHR_HUMAN","http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field\u003duid\u0026exact\u003dFind+Exact+Term\u0026term\u003dD013961","http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field\u003duid\u0026exact\u003dFind+Exact+Term\u0026term\u003dD013959","http://www.uniprot.org/uniprot/TSHB_CANFA","http://www.uniprot.org/uniprot/TSHB_SALSA","http://www.uniprot.org/uniprot/TSHB_CHICK","http://www.uniprot.org/uniprot/TSHB_ANGAN","http://www.uniprot.org/uniprot/TSHB_FELCA","http://www.uniprot.org/uniprot/TSHB_BOVIN","http://www.uniprot.org/uniprot/TSHB_MOUSE","http://www.uniprot.org/uniprot/TSHB_ONCMY","http://www.uniprot.org/uniprot/TSHB_HORSE","http://www.uniprot.org/uniprot/TSHB_MONDO","http://www.uniprot.org/uniprot/TSHB_RAT","http://www.uniprot.org/uniprot/TSHB_PIG","http://www.uniprot.org/uniprot/TSHB_LAMGL","http://www.uniprot.org/uniprot/TSHB_PHOSU","http://www.uniprot.org/uniprot/TSHB_ANGJA","http://www.uniprot.org/uniprot/TSHB_HUMAN","http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field\u003duid\u0026exact\u003dFind+Exact+Term\u0026term\u003dD037322","http://www.biosemantics.org/jochem#4250044","http://www.uniprot.org/uniprot/TRFR_CHICK","http://www.uniprot.org/uniprot/TRFR_BOVIN","http://www.uniprot.org/uniprot/TRFR_HUMAN","http://www.uniprot.org/uniprot/TRFR_RAT","http://www.uniprot.org/uniprot/TRFR_MOUSE","http://www.uniprot.org/uniprot/TRFR_SHEEP","http://www.uniprot.org/uniprot/THBA_XENLA","http://www.uniprot.org/uniprot/THB_CAIMO","http://www.uniprot.org/uniprot/THB_PAROL","http://www.uniprot.org/uniprot/THB_SHEEP","http://www.uniprot.org/uniprot/THB_RAT","http://www.uniprot.org/uniprot/THB_MOUSE","http://www.uniprot.org/uniprot/THB_DANRE","http://www.uniprot.org/uniprot/THB_HUMAN","http://www.uniprot.org/uniprot/THB_LITCT","http://www.uniprot.org/uniprot/THB_CHICK","http://www.uniprot.org/uniprot/THA_CAIMO","http://www.uniprot.org/uniprot/THA_APTPA","http://www.uniprot.org/uniprot/THAA_PAROL","http://www.uniprot.org/uniprot/THA_PIG","http://www.uniprot.org/uniprot/THA_SHEEP","http://www.uniprot.org/uniprot/THA_HIPHI","http://www.uniprot.org/uniprot/THAA_DANRE","http://www.uniprot.org/uniprot/THA_ELECQ","http://www.uniprot.org/uniprot/THA_RAT","http://www.uniprot.org/uniprot/THA_NECMA","http://www.uniprot.org/uniprot/THAA_XENLA","http://www.uniprot.org/uniprot/THA_PYGAD","http://www.uniprot.org/uniprot/THA_SPAAU","http://www.uniprot.org/uniprot/THA_HUMAN","http://www.uniprot.org/uniprot/THA_CHICK","http://www.uniprot.org/uniprot/THA_MOUSE","http://www.uniprot.org/uniprot/THA_LITCT","http://www.uniprot.org/uniprot/THA_SALSA","http://www.uniprot.org/uniprot/THA_ONCMY","http://amigo.geneontology.org/cgi-bin/amigo/term_details?term\u003dGO:0004887","http://amigo.geneontology.org/cgi-bin/amigo/term_details?term\u003dGO:0046966","http://amigo.geneontology.org/cgi-bin/amigo/term_details?term\u003dGO:0070460","http://www.uniprot.org/uniprot/TSH_ECOLX","http://www.uniprot.org/uniprot/TRIP6_BOVIN","http://www.uniprot.org/uniprot/TRIP6_MOUSE","http://www.uniprot.org/uniprot/TRIP6_HUMAN","http://amigo.geneontology.org/cgi-bin/amigo/term_details?term\u003dGO:0004996","http://amigo.geneontology.org/cgi-bin/amigo/term_details?term\u003dGO:0010861","http://amigo.geneontology.org/cgi-bin/amigo/term_details?term\u003dGO:0004997","http://amigo.geneontology.org/cgi-bin/amigo/term_details?term\u003dGO:0031531","http://amigo.geneontology.org/cgi-bin/amigo/term_details?term\u003dGO:2000612","http://amigo.geneontology.org/cgi-bin/amigo/term_details?term\u003dGO:0030375","http://www.uniprot.org/uniprot/TSH_DROME","http://www.uniprot.org/uniprot/MED1_HUMAN","http://www.uniprot.org/uniprot/MED1_MOUSE","http://www.uniprot.org/uniprot/ZNHI3_MACMU","http://www.uniprot.org/uniprot/ZNHI3_MOUSE","http://www.uniprot.org/uniprot/ZNHI3_PANTR","http://www.uniprot.org/uniprot/ZNHI3_HUMAN","http://www.uniprot.org/uniprot/KIF11_HUMAN","http://www.uniprot.org/uniprot/TRIP4_MOUSE","http://www.uniprot.org/uniprot/TRIP4_HUMAN","http://www.uniprot.org/uniprot/NCOA6_RAT","http://www.uniprot.org/uniprot/NCOA6_MOUSE","http://www.uniprot.org/uniprot/NCOA6_HUMAN","http://www.uniprot.org/uniprot/HMGN3_HUMAN","http://www.uniprot.org/uniprot/GLHA_MONDO","http://www.uniprot.org/uniprot/GLHA_MACMU","http://www.uniprot.org/uniprot/GLHA_LITCT","http://www.uniprot.org/uniprot/GLHA_BALAC","http://www.uniprot.org/uniprot/GLHA_AILFU","http://www.uniprot.org/uniprot/GLHA_MELGA","http://www.uniprot.org/uniprot/GLHA_TRIVU","http://www.uniprot.org/uniprot/GLHA_BUBBU","http://www.uniprot.org/uniprot/GLHA_MACRU","http://www.uniprot.org/uniprot/GLHA_SAIBB","http://www.uniprot.org/uniprot/GLHA_BOSMU","http://www.uniprot.org/uniprot/GLHA_CAPHI","http://www.uniprot.org/uniprot/GLHA_MACFA","http://www.uniprot.org/uniprot/GLHA_PHYMC","http://www.uniprot.org/uniprot/GLHA_CALJA","http://www.uniprot.org/uniprot/GLHA_STRCA","http://www.uniprot.org/uniprot/GLHA_EQUBU","http://www.uniprot.org/uniprot/GLHA_CAVPO","http://www.uniprot.org/uniprot/GLHA_NIPNI","http://www.uniprot.org/uniprot/GLHA_HUMAN","http://www.uniprot.org/uniprot/GLHA_SHEEP","http://www.uniprot.org/uniprot/GLHA_CANFA","http://www.uniprot.org/uniprot/GLHA_MICMO","http://www.disease-ontology.org/api/metadata/DOID:7166","http://amigo.geneontology.org/cgi-bin/amigo/term_details?term\u003dGO:0001104","http://www.biosemantics.org/jochem#4272302","http://www.biosemantics.org/jochem#4250003","http://www.biosemantics.org/jochem#4195746","http://www.biosemantics.org/jochem#4272308","http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field\u003duid\u0026exact\u003dFind+Exact+Term\u0026term\u003dD013966","http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field\u003duid\u0026exact\u003dFind+Exact+Term\u0026term\u003dD052684","http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field\u003duid\u0026exact\u003dFind+Exact+Term\u0026term\u003dD015292","http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field\u003duid\u0026exact\u003dFind+Exact+Term\u0026term\u003dD056913"],"triples":[{"s":"http://linkedlifedata.com/resource/umls/id/C0182698","p":"http://linkedlifedata.com/resource/umls/prefMetaMap"},{"p":"http://www.w3.org/1999/02/22-rdf-syntax-ns#type","o":"http://www.w3.org/2008/05/skos-xl#Label"},{"p":"http://www.w3.org/2004/02/skos/core#notation","o":"17-283"},{"p":"http://www.w3.org/2004/02/skos/core#note","o":"UMDNS"},{"p":"http://www.w3.org/2008/05/skos-xl#literalForm","o":"Reagents, Immunoassay, Autoimmune, Thyroid, Thyrotropin Receptor Antibody"},{"s":"http://linkedlifedata.com/resource/umls/id/C0182698","p":"http://www.w3.org/2008/05/skos-xl#prefLabel"},{"p":"http://www.w3.org/1999/02/22-rdf-syntax-ns#type","o":"http://www.w3.org/2008/05/skos-xl#Label"},{"p":"http://www.w3.org/2004/02/skos/core#notation","o":"MTHU026394"},{"p":"http://www.w3.org/2004/02/skos/core#note","o":"OMIM"},{"p":"http://www.w3.org/2008/05/skos-xl#literalForm","o":"Low or absent thyrotropin (TSH)"},{"s":"http://linkedlifedata.com/resource/umls/id/C2750030","p":"http://www.w3.org/2008/05/skos-xl#prefLabel"},{"p":"http://www.w3.org/1999/02/22-rdf-syntax-ns#type","o":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugbank/targets"},{"p":"http://www.w3.org/2000/01/rdf-schema#label","o":"Thyrotropin receptor"},{"p":"http://www.w3.org/2004/02/skos/core#exactMatch","o":"http://www.dbpedia.org/resource/Thyrotropin_receptor"},{"p":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugbank/bio2rdfSymbol","o":"http://symbol.bio2rdf.org/symbol:TSHR"},{"p":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugbank/cellularLocation","o":"membrane"},{"p":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugbank/cellularLocation","o":"multi-passMembraneProtein"},{"p":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugbank/chromosomeLocation","o":"14"},{"p":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugbank/drugReference","o":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/15571461"},{"p":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugbank/drugReference","o":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/9039330"},{"p":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugbank/essentiality","o":"Non-Essential"},{"p":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugbank/genatlasId","o":"TSHR"},{"p":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugbank/genbankIdGene","o":"M73747"},{"p":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugbank/genbankIdGenePage","o":"http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val\u003dM73747"},{"p":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugbank/genbankIdProtein","o":"903760"},{"p":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugbank/genbankIdProteinPage","o":"http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val\u003d903760"},{"p":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugbank/genecardId","o":"TSHR"},{"p":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugbank/geneName","o":"TSHR"},{"p":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugbank/generalFunction","o":"Involved in rhodopsin-like receptor activity"},{"p":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugbank/generalReference","o":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/10037070"},{"p":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugbank/generalReference","o":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/10199795"},{"p":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugbank/generalReference","o":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/10487707"},{"p":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugbank/generalReference","o":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/10560955"},{"p":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugbank/generalReference","o":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/10651846"},{"p":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugbank/generalReference","o":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/10720030"},{"p":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugbank/generalReference","o":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/10852462"},{"p":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugbank/generalReference","o":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/10870027"},{"p":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugbank/generalReference","o":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/10946859"},{"p":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugbank/generalReference","o":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/11022192"},{"p":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugbank/generalReference","o":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/11081252"},{"p":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugbank/generalReference","o":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/11095460"},{"p":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugbank/generalReference","o":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/11127522"},{"p":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugbank/generalReference","o":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/11128715"},{"p":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugbank/generalReference","o":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/11201847"},{"p":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugbank/generalReference","o":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/11434721"},{"p":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugbank/generalReference","o":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/11442002"},{"p":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugbank/generalReference","o":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/11502179"},{"p":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugbank/generalReference","o":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/11517004"},{"p":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugbank/generalReference","o":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/11549687"},{"p":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugbank/generalReference","o":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/11887032"},{"p":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugbank/generalReference","o":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/12045258"},{"p":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugbank/generalReference","o":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/12050212"},{"p":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugbank/generalReference","o":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/12213664"},{"p":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugbank/generalReference","o":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/12589819"},{"p":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugbank/generalReference","o":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/12593721"},{"p":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugbank/generalReference","o":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/12788902"},{"p":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugbank/generalReference","o":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/12930595"},{"p":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugbank/generalReference","o":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/1530609"},{"p":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugbank/generalReference","o":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/1955520"},{"p":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugbank/generalReference","o":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/2293030"},{"p":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugbank/generalReference","o":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/2302212"},{"p":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugbank/generalReference","o":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/2558651"},{"p":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugbank/generalReference","o":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/2610690"},{"p":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugbank/generalReference","o":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/7488864"},{"p":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugbank/generalReference","o":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/7508946"},{"p":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugbank/generalReference","o":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/7528344"},{"p":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugbank/generalReference","o":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/7556878"},{"p":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugbank/generalReference","o":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/7647578"},{"p":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugbank/generalReference","o":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/7800007"},{"p":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugbank/generalReference","o":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/7920658"},{"p":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugbank/generalReference","o":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/7989485"},{"p":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugbank/generalReference","o":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/8045989"},{"p":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugbank/generalReference","o":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/8413627"},{"p":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugbank/generalReference","o":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/8636266"},{"p":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugbank/generalReference","o":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/8747461"},{"p":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugbank/generalReference","o":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/8954020"},{"p":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugbank/generalReference","o":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/8964822"},{"p":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugbank/generalReference","o":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/9062474"},{"p":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugbank/generalReference","o":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/9100579"},{"p":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugbank/generalReference","o":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/9185526"},{"p":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugbank/generalReference","o":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/9253356"},{"p":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugbank/generalReference","o":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/9294132"},{"p":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugbank/generalReference","o":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/9329388"},{"p":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugbank/generalReference","o":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/9349581"},{"p":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugbank/generalReference","o":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/9360555"},{"p":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugbank/generalReference","o":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/9398746"},{"p":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugbank/generalReference","o":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/9589634"},{"p":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugbank/generalReference","o":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/9854118"},{"p":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugbank/geneSequence","o":"\u003e2292 bp\nATGAGGCCGGCGGACTTGCTGCAGCTGGTGCTGCTGCTCGACCTGCCCAGGGACCTGGGC\nGGAATGGGGTGTTCGTCTCCACCCTGCGAGTGCCATCAGGAGGAGGACTTCAGAGTCACC\nTGCAAGGATATTCAACGCATCCCCAGCTTACCGCCCAGTACGCAGACTCTGAAGCTTATT\nGAGACTCACCTGAGAACTATTCCAAGTCATGCATTTTCTAATCTGCCCAATATTTCCAGA\nATCTACGTATCTATAGATGTGACTCTGCAGCAGCTGGAATCACACTCCTTCTACAATTTG\nAGTAAAGTGACTCACATAGAAATTCGGAATACCAGGAACTTAACTTACATAGACCCTGAT\nGCCCTCAAAGAGCTCCCCCTCCTAAAGTCCTTGGCATTTTCAAACACTGGACTTAAAATG\nTTCCCTGACCTGACCAAAGTTTATTCCACTGATATATTCTTTATACTTGAAATTACAGAC\nAACCCTTACATGACGTCAATCCCTGTGAATGCTTTTCAGGGACTATGCAATGAAACCTTG\nACACTGAAGCTGTACAACAATGGCTTTACTTCAGTCCAAGGATATGATTTCTTTGGGACA\nAAGCTGGATGCTGTTTACCTAAACAAGAATAAATACCTGACAGTTATTGACAAAGATGCA\nTTTGGAGGAGTATACAGTGGACCAAGCTTGCTGGACGTGTCTCAAACCAGTGTCACTGCC\nCTTCCATCCAAAGGCCTGGAGCACCTGAAGGAACTGATAGCAAGAAACAGCTGGACTCTT\nAAGAAACTTGCACTTTCCTTGAGTTTCCTTCACCTCACACGGGCTGACCTTTCTTACCCA\nAGCCACTGCTGTGCTTTTAAGAATCAGAAGAAAATCAGAGGAATCCTTGAGTCCTTGATG\nTGTAATGAGAGCAGTATCGAGACGTTGCGCCAGAGAAAATCTGTGAATGCCTTGAATAGC\nCCCCTCCACCAGGAATATGAAGAGAATCTGGGTGACAGCATTGTTGGGTACAAGGAAAAG\nTCCAAGTTCCAGGATACTCATAACAACGCTCATTATTACGTCTTCTTTGAAGAACAAGAG\nGATGAGATCATTGGTTTTGGCCAGGAGCTCAAAAACCCCCAGGAAGAGACTCTACAAGCT\nTTTGACAGCCATTATGACTACACCATATGTGGGGACAGTGAAGACATGGTGTGTACCCCC\nAAGTCCGATGAGTTCAACCCGTGTGAAGACATAATGGGCTACAAGTTCCTGAGAATTGTG\nGTGTGGTTCGTTAGTCTGCTGGCTCTCCTGGGCAATGTCTTTGTCCTGCTTATTCTCCTC\nACCAGCCACTACAAACTGAACGTCCCCCGCTTTCTCATGTGCAACCTGGCCTTTGCGGAT\nTTCTGCATGGGGATGTACCTGCTCCTCATCGCCTCTGTAGACCTCTACACTCACTCTGAG\nTACTACAACCATGCCATCGACTGGCAGACAGGCCCTGGGTGCAACACGGCTGGTTTCTTC\nACTGTCTTTGCAAGCGAGTTATCGGTGTATACGCTGACGGTCATCACCCTGGAGCGCTGG\nTATGCCATCACCTTCGCCATGGCCCTGGACCGGAAGATCCGCCTCAGGCACGCATGTGCC\nATCATGGTTGGGGGCTGGGTTTGCTGCTTCCTTCTCGCCCTGCTTCCTTTGGTGGGAATA\nAGTAGCTATGCCAAAGTCAGTATCTGCCTGCCCATGGACACCGAGACCCCTCTTGCTCTG\nGCATATATTGTTTTTGTTCTGACGCTCAACATAGTTGCCTTCGTCATCGTCTGCTGCTGT\nTATGTGAAGATCTACATCACAGTCCGAAATCCGCACAACCCAGGGGACAAAGATACCAAA\nATTGCCAAGAGGATGGCTGTGTTGATCTTCACCGACTTCACGTGCATGGCCCCAATCTCA\nTTCTATGCTGTGTCAGCAATTCTGAACAAGCCTCTCATCACTGTTAGCAACTCCAAAATC\nTTGCTGGTACTCTTCTATCCAATTAACTCCTGTGCCAATCCATTCCTCTATGCTATTTTC\nACCAAGGCCTTCCAGAGGGATGTGTTCATCCTACTCAGCAAGTTTGGCATCTGTAAACGC\nCAGGCTCAGGCATACCGGGGGCAGAGGGTTCCTCCAAAGAACAGCACTGATATTCAGGTT\nCAAAAGGTTACCCACGACATGAGGCAGGGTCTCCACAACATGGAAGATGTCTATGAACTG\nATTGAAAACTCCCATCTAACCCCAAAGAAGCAAGGCCAAATCTCAGAAGAGTATATGCAA\nACGGTTTTGTAA"},{"p":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugbank/goClassificationComponent","o":"cell"},{"p":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugbank/goClassificationComponent","o":"integral to membrane"},{"p":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugbank/goClassificationComponent","o":"intrinsic to membrane"},{"p":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugbank/goClassificationComponent","o":"membrane"},{"p":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugbank/goClassificationFunction","o":"G-protein coupled receptor activity"},{"p":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugbank/goClassificationFunction","o":"protein-hormone receptor activity"},{"p":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugbank/goClassificationFunction","o":"receptor activity"},{"p":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugbank/goClassificationFunction","o":"rhodopsin-like receptor activity"},{"p":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugbank/goClassificationFunction","o":"signal transducer activity"},{"p":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugbank/goClassificationFunction","o":"transmembrane receptor activity"},{"p":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugbank/goClassificationProcess","o":"cell communication"},{"p":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugbank/goClassificationProcess","o":"cell surface receptor linked signal transduction"},{"p":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugbank/goClassificationProcess","o":"cellular process"},{"p":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugbank/goClassificationProcess","o":"G-protein coupled receptor protein signaling pathway"},{"p":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugbank/goClassificationProcess","o":"signal transduction"},{"p":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugbank/hgncId","o":"http://bio2rdf.org/hgnc:12373"},{"p":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugbank/hgncIdPage","o":"http://www.genenames.org/data/hgnc_data.php?hgnc_id\u003d12373"},{"p":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugbank/hprdId","o":"04537"},{"p":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugbank/locus","o":"14q31"},{"p":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugbank/molecularWeight","o":"86831"},{"p":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugbank/name","o":"Thyrotropin receptor"},{"p":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugbank/numberOfResidues","o":"776"},{"p":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugbank/pfamDomainFunction","o":"http://bio2rdf.org/pfam:PF00001"},{"p":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugbank/pfamDomainFunction","o":"http://bio2rdf.org/pfam:PF00560"},{"p":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugbank/pfamDomainFunctionPage","o":"http://pfam.sanger.ac.uk/family?acc\u003dPF00001"},{"p":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugbank/pfamDomainFunctionPage","o":"http://pfam.sanger.ac.uk/family?acc\u003dPF00560"},{"p":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugbank/proteinSequence","o":"\u003eThyrotropin receptor precursor\nMRPADLLQLVLLLDLPRDLGGMGCSSPPCECHQEEDFRVTCKDIQRIPSLPPSTQTLKLI\nETHLRTIPSHAFSNLPNISRIYVSIDVTLQQLESHSFYNLSKVTHIEIRNTRNLTYIDPD\nALKELPLLKFLGIFNTGLKMFPDLTKVYSTDIFFILEITDNPYMTSIPVNAFQGLCNETL\nTLKLYNNGFTSVQGYAFNGTKLDAVYLNKNKYLTVIDKDAFGGVYSGPSLLDVSQTSVTA\nLPSKGLEHLKELIARNTWTLKKLPLSLSFLHLTRADLSYPSHCCAFKNQKKIRGILESLM\nCNESSMQSLRQRKSVNALNSPLHQEYEENLGDSIVGYKEKSKFQDTHNNAHYYVFFEEQE\nDEIIGFGQELKNPQEETLQAFDSHYDYTICGDSEDMVCTPKSDEFNPCEDIMGYKFLRIV\nVWFVSLLALLGNVFVLLILLTSHYKLNVPRFLMCNLAFADFCMGMYLLLIASVDLYTHSE\nYYNHAIDWQTGPGCNTAGFFTVFASELSVYTLTVITLERWYAITFAMRLDRKIRLRHACA\nIMVGGWVCCFLLALLPLVGISSYAKVSICLPMDTETPLALAYIVFVLTLNIVAFVIVCCC\nYVKIYITVRNPQYNPGDKDTKIAKRMAVLIFTDFICMAPISFYALSAILNKPLITVSNSK\nILLVLFYPLNSCANPFLYAIFTKAFQRDVFILLSKFGICKRQAQAYRGQRVPPKNSTDIQ\nVQKVTHDMRQGLHNMEDVYELIENSHLTPKKQGQISEEYMQTVL"},{"p":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugbank/signal","o":"1-20"},{"p":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugbank/specificFunction","o":"Receptor for thyrothropin. Plays a central role in controlling thyroid cell metabolism. The activity of this receptor is mediated by G proteins which activate adenylate cyclase. Also acts as a receptor for thyrostimulin (GPA2+GPB5)"},{"p":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugbank/swissprotId","o":"http://bio2rdf.org/uniprot:P16473"},{"p":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugbank/swissprotName","o":"TSHR_HUMAN"},{"p":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugbank/swissprotPage","o":"http://www.uniprot.org/uniprot/P16473"},{"p":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugbank/synonym","o":"Thyroid-stimulating hormone receptor"},{"p":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugbank/synonym","o":"Thyrotropin receptor precursor"},{"p":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugbank/synonym","o":"TSH-R"},{"s":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00024","p":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugbank/target"},{"p":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugbank/theoreticalPi","o":"6.98"},{"p":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugbank/transmembraneRegions","o":"414-441"},{"p":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugbank/transmembraneRegions","o":"451-473"},{"p":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugbank/transmembraneRegions","o":"495-517"},{"p":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugbank/transmembraneRegions","o":"538-560"},{"p":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugbank/transmembraneRegions","o":"581-602"},{"p":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugbank/transmembraneRegions","o":"626-649"},{"p":"http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugbank/transmembraneRegions","o":"661-682"},{"s":"http://linkedlifedata.com/resource/umls/id/C0034844","p":"http://linkedlifedata.com/resource/umls/altMetaMap"},{"p":"http://www.w3.org/1999/02/22-rdf-syntax-ns#type","o":"http://www.w3.org/2008/05/skos-xl#Label"},{"p":"http://www.w3.org/2004/02/skos/core#notation","o":"C30133"},{"p":"http://www.w3.org/2004/02/skos/core#note","o":"NCI Thesaurus"},{"s":"http://linkedlifedata.com/resource/umls/id/C0034844","p":"http://www.w3.org/2008/05/skos-xl#altLabel"},{"p":"http://www.w3.org/2008/05/skos-xl#literalForm","o":"Thyrotropin Receptor"}]},{"exact_answer":[["abc","def"],["abc","def"]],"ideal_answer":"pseudo ideal answer","id":"51477de5d24251bc05000020","body":"Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome?","type":"list","documents":["http://www.ncbi.nlm.nih.gov/pubmed/9681845"],"snippets":[],"concepts":["http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field\u003duid\u0026exact\u003dFind+Exact+Term\u0026term\u003dD018761","http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field\u003duid\u0026exact\u003dFind+Exact+Term\u0026term\u003dD018813","http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field\u003duid\u0026exact\u003dFind+Exact+Term\u0026term\u003dD018814","http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field\u003duid\u0026exact\u003dFind+Exact+Term\u0026term\u003dD009377","http://www.uniprot.org/uniprot/MMTA2_HUMAN","http://www.uniprot.org/uniprot/MMTA2_RAT","http://www.uniprot.org/uniprot/MMTA2_MOUSE","http://www.uniprot.org/uniprot/MMTA2_BOVIN","http://www.disease-ontology.org/api/metadata/DOID:10017","http://www.disease-ontology.org/api/metadata/DOID:0050430","http://www.disease-ontology.org/api/metadata/DOID:10016","http://www.disease-ontology.org/api/metadata/DOID:170","http://www.disease-ontology.org/api/metadata/DOID:10193","http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field\u003duid\u0026exact\u003dFind+Exact+Term\u0026term\u003dD009102","http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field\u003duid\u0026exact\u003dFind+Exact+Term\u0026term\u003dD009384","http://www.disease-ontology.org/api/metadata/DOID:0060089","http://www.uniprot.org/uniprot/CD2A1_HUMAN","http://www.uniprot.org/uniprot/DNJC4_HUMAN","http://www.uniprot.org/uniprot/DNJC4_MOUSE","http://www.uniprot.org/uniprot/CDN2B_HUMAN","http://www.uniprot.org/uniprot/TRAP1_HUMAN","http://www.uniprot.org/uniprot/TRAP1_RAT","http://www.uniprot.org/uniprot/TRAP1_BOVIN","http://www.uniprot.org/uniprot/TRAP1_MOUSE","http://www.uniprot.org/uniprot/PSMD2_BOVIN","http://www.uniprot.org/uniprot/PSMD2_HUMAN","http://www.biosemantics.org/jochem#4197418","http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field\u003duid\u0026exact\u003dFind+Exact+Term\u0026term\u003dD016884","http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field\u003duid\u0026exact\u003dFind+Exact+Term\u0026term\u003dD016162","http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field\u003duid\u0026exact\u003dFind+Exact+Term\u0026term\u003dD019941","http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field\u003duid\u0026exact\u003dFind+Exact+Term\u0026term\u003dD009369"],"triples":[{"s":"http://linkedlifedata.com/resource/umls/id/C0025267","p":"http://linkedlifedata.com/resource/umls/altMetaMap"},{"p":"http://www.w3.org/1999/02/22-rdf-syntax-ns#type","o":"http://www.w3.org/2008/05/skos-xl#Label"},{"p":"http://www.w3.org/2004/02/skos/core#notation","o":"N0000003850"},{"p":"http://www.w3.org/2004/02/skos/core#note","o":"National Drug File - Reference Terminology"},{"s":"http://linkedlifedata.com/resource/umls/id/C0025267","p":"http://www.w3.org/2008/05/skos-xl#altLabel"},{"p":"http://www.w3.org/2008/05/skos-xl#literalForm","o":"Multiple Endocrine Neoplasia Type 1"},{"s":"http://linkedlifedata.com/resource/umls/id/C0025267","p":"http://linkedlifedata.com/resource/umls/altMetaMap"},{"p":"http://www.w3.org/1999/02/22-rdf-syntax-ns#type","o":"http://www.w3.org/2008/05/skos-xl#Label"},{"p":"http://www.w3.org/2004/02/skos/core#notation","o":"D018761"},{"p":"http://www.w3.org/2004/02/skos/core#note","o":"MeSH"},{"s":"http://linkedlifedata.com/resource/umls/id/C0025267","p":"http://www.w3.org/2008/05/skos-xl#altLabel"},{"p":"http://www.w3.org/2008/05/skos-xl#literalForm","o":"Multiple Endocrine Neoplasia Type 1"},{"s":"http://linkedlifedata.com/resource/umls/id/C0025267","p":"http://linkedlifedata.com/resource/umls/altMetaMap"},{"p":"http://www.w3.org/1999/02/22-rdf-syntax-ns#type","o":"http://www.w3.org/2008/05/skos-xl#Label"},{"p":"http://www.w3.org/2004/02/skos/core#notation","o":"N0000003850"},{"p":"http://www.w3.org/2004/02/skos/core#note","o":"National Drug File - Reference Terminology"},{"s":"http://linkedlifedata.com/resource/umls/id/C0025267","p":"http://www.w3.org/2008/05/skos-xl#altLabel"},{"p":"http://www.w3.org/2008/05/skos-xl#literalForm","o":"Neoplasia, Multiple Endocrine Type 1"},{"s":"http://linkedlifedata.com/resource/umls/id/C0025267","p":"http://linkedlifedata.com/resource/umls/altMetaMap"},{"p":"http://www.w3.org/1999/02/22-rdf-syntax-ns#type","o":"http://www.w3.org/2008/05/skos-xl#Label"},{"p":"http://www.w3.org/2004/02/skos/core#notation","o":"D018761"},{"p":"http://www.w3.org/2004/02/skos/core#note","o":"MeSH"},{"s":"http://linkedlifedata.com/resource/umls/id/C0025267","p":"http://www.w3.org/2008/05/skos-xl#altLabel"},{"p":"http://www.w3.org/2008/05/skos-xl#literalForm","o":"Neoplasia, Multiple Endocrine Type 1"}]},{"exact_answer":[["abc","def"],["abc","def"]],"ideal_answer":"pseudo ideal answer","id":"5149199dd24251bc05000040","body":"Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis?","type":"list","documents":["http://www.ncbi.nlm.nih.gov/pubmed/21328290","http://www.ncbi.nlm.nih.gov/pubmed/20927659","http://www.ncbi.nlm.nih.gov/pubmed/18684515","http://www.ncbi.nlm.nih.gov/pubmed/20345342","http://www.ncbi.nlm.nih.gov/pubmed/22037997","http://www.ncbi.nlm.nih.gov/pubmed/21180568","http://www.ncbi.nlm.nih.gov/pubmed/17658970","http://www.ncbi.nlm.nih.gov/pubmed/23117946","http://www.ncbi.nlm.nih.gov/pubmed/20842584","http://www.ncbi.nlm.nih.gov/pubmed/17986328","http://www.ncbi.nlm.nih.gov/pubmed/21815707","http://www.ncbi.nlm.nih.gov/pubmed/18936425","http://www.ncbi.nlm.nih.gov/pubmed/22805122","http://www.ncbi.nlm.nih.gov/pubmed/18069667","http://www.ncbi.nlm.nih.gov/pubmed/18854691","http://www.ncbi.nlm.nih.gov/pubmed/18024782","http://www.ncbi.nlm.nih.gov/pubmed/19999149","http://www.ncbi.nlm.nih.gov/pubmed/24145588","http://www.ncbi.nlm.nih.gov/pubmed/23823963","http://www.ncbi.nlm.nih.gov/pubmed/23242891","http://www.ncbi.nlm.nih.gov/pubmed/22091897","http://www.ncbi.nlm.nih.gov/pubmed/19271944","http://www.ncbi.nlm.nih.gov/pubmed/19260048","http://www.ncbi.nlm.nih.gov/pubmed/18505362","http://www.ncbi.nlm.nih.gov/pubmed/18176295","http://www.ncbi.nlm.nih.gov/pubmed/20411231","http://www.ncbi.nlm.nih.gov/pubmed/19942297","http://www.ncbi.nlm.nih.gov/pubmed/19205361","http://www.ncbi.nlm.nih.gov/pubmed/19146644","http://www.ncbi.nlm.nih.gov/pubmed/18567872","http://www.ncbi.nlm.nih.gov/pubmed/21631705","http://www.ncbi.nlm.nih.gov/pubmed/20491896","http://www.ncbi.nlm.nih.gov/pubmed/24141560","http://www.ncbi.nlm.nih.gov/pubmed/23337001","http://www.ncbi.nlm.nih.gov/pubmed/23279780","http://www.ncbi.nlm.nih.gov/pubmed/22311063","http://www.ncbi.nlm.nih.gov/pubmed/21532824","http://www.ncbi.nlm.nih.gov/pubmed/21397501","http://www.ncbi.nlm.nih.gov/pubmed/20486100","http://www.ncbi.nlm.nih.gov/pubmed/20166870","http://www.ncbi.nlm.nih.gov/pubmed/20001782","http://www.ncbi.nlm.nih.gov/pubmed/19237289","http://www.ncbi.nlm.nih.gov/pubmed/19209651","http://www.ncbi.nlm.nih.gov/pubmed/18605252","http://www.ncbi.nlm.nih.gov/pubmed/18567877","http://www.ncbi.nlm.nih.gov/pubmed/17711430","http://www.ncbi.nlm.nih.gov/pubmed/17538742","http://www.ncbi.nlm.nih.gov/pubmed/19401508","http://www.ncbi.nlm.nih.gov/pubmed/21236521","http://www.ncbi.nlm.nih.gov/pubmed/24088269","http://www.ncbi.nlm.nih.gov/pubmed/23670841","http://www.ncbi.nlm.nih.gov/pubmed/23235620","http://www.ncbi.nlm.nih.gov/pubmed/21133188","http://www.ncbi.nlm.nih.gov/pubmed/21053987","http://www.ncbi.nlm.nih.gov/pubmed/20105151","http://www.ncbi.nlm.nih.gov/pubmed/20058740","http://www.ncbi.nlm.nih.gov/pubmed/19852027","http://www.ncbi.nlm.nih.gov/pubmed/19836041","http://www.ncbi.nlm.nih.gov/pubmed/19127534","http://www.ncbi.nlm.nih.gov/pubmed/18952242","http://www.ncbi.nlm.nih.gov/pubmed/18514130","http://www.ncbi.nlm.nih.gov/pubmed/18018839","http://www.ncbi.nlm.nih.gov/pubmed/17537383","http://www.ncbi.nlm.nih.gov/pubmed/20225980","http://www.ncbi.nlm.nih.gov/pubmed/23909021","http://www.ncbi.nlm.nih.gov/pubmed/23559196","http://www.ncbi.nlm.nih.gov/pubmed/23423465","http://www.ncbi.nlm.nih.gov/pubmed/22768972","http://www.ncbi.nlm.nih.gov/pubmed/22216416","http://www.ncbi.nlm.nih.gov/pubmed/22043769","http://www.ncbi.nlm.nih.gov/pubmed/21845054","http://www.ncbi.nlm.nih.gov/pubmed/21788239","http://www.ncbi.nlm.nih.gov/pubmed/20854638","http://www.ncbi.nlm.nih.gov/pubmed/22798513","http://www.ncbi.nlm.nih.gov/pubmed/19395293","http://www.ncbi.nlm.nih.gov/pubmed/19349707","http://www.ncbi.nlm.nih.gov/pubmed/19339286","http://www.ncbi.nlm.nih.gov/pubmed/19233080","http://www.ncbi.nlm.nih.gov/pubmed/18769095","http://www.ncbi.nlm.nih.gov/pubmed/18590268","http://www.ncbi.nlm.nih.gov/pubmed/17464478","http://www.ncbi.nlm.nih.gov/pubmed/23938353","http://www.ncbi.nlm.nih.gov/pubmed/23678983","http://www.ncbi.nlm.nih.gov/pubmed/23172384","http://www.ncbi.nlm.nih.gov/pubmed/22957965","http://www.ncbi.nlm.nih.gov/pubmed/21969350","http://www.ncbi.nlm.nih.gov/pubmed/21532382","http://www.ncbi.nlm.nih.gov/pubmed/20678749","http://www.ncbi.nlm.nih.gov/pubmed/20645565","http://www.ncbi.nlm.nih.gov/pubmed/19808197","http://www.ncbi.nlm.nih.gov/pubmed/19760347","http://www.ncbi.nlm.nih.gov/pubmed/19433668","http://www.ncbi.nlm.nih.gov/pubmed/19375665","http://www.ncbi.nlm.nih.gov/pubmed/19330280","http://www.ncbi.nlm.nih.gov/pubmed/18567856","http://www.ncbi.nlm.nih.gov/pubmed/18155768","http://www.ncbi.nlm.nih.gov/pubmed/17464475","http://www.ncbi.nlm.nih.gov/pubmed/17415507","http://www.ncbi.nlm.nih.gov/pubmed/20138518","http://www.ncbi.nlm.nih.gov/pubmed/18271233","http://www.ncbi.nlm.nih.gov/pubmed/24164490","http://www.ncbi.nlm.nih.gov/pubmed/23768983","http://www.ncbi.nlm.nih.gov/pubmed/23535158","http://www.ncbi.nlm.nih.gov/pubmed/23381166","http://www.ncbi.nlm.nih.gov/pubmed/23376659","http://www.ncbi.nlm.nih.gov/pubmed/23278573","http://www.ncbi.nlm.nih.gov/pubmed/23252901","http://www.ncbi.nlm.nih.gov/pubmed/23051847","http://www.ncbi.nlm.nih.gov/pubmed/22973658","http://www.ncbi.nlm.nih.gov/pubmed/22883288","http://www.ncbi.nlm.nih.gov/pubmed/22525448","http://www.ncbi.nlm.nih.gov/pubmed/21854656","http://www.ncbi.nlm.nih.gov/pubmed/21296574","http://www.ncbi.nlm.nih.gov/pubmed/20187712","http://www.ncbi.nlm.nih.gov/pubmed/18095502","http://www.ncbi.nlm.nih.gov/pubmed/19327804","http://www.ncbi.nlm.nih.gov/pubmed/24095170","http://www.ncbi.nlm.nih.gov/pubmed/23537506","http://www.ncbi.nlm.nih.gov/pubmed/22337799","http://www.ncbi.nlm.nih.gov/pubmed/22316202","http://www.ncbi.nlm.nih.gov/pubmed/22102461","http://www.ncbi.nlm.nih.gov/pubmed/21970202","http://www.ncbi.nlm.nih.gov/pubmed/21784757","http://www.ncbi.nlm.nih.gov/pubmed/20613516","http://www.ncbi.nlm.nih.gov/pubmed/20586729","http://www.ncbi.nlm.nih.gov/pubmed/19143167","http://www.ncbi.nlm.nih.gov/pubmed/18767335","http://www.ncbi.nlm.nih.gov/pubmed/18411583","http://www.ncbi.nlm.nih.gov/pubmed/18340510","http://www.ncbi.nlm.nih.gov/pubmed/17459760","http://www.ncbi.nlm.nih.gov/pubmed/22981737","http://www.ncbi.nlm.nih.gov/pubmed/23893883","http://www.ncbi.nlm.nih.gov/pubmed/22057263","http://www.ncbi.nlm.nih.gov/pubmed/21681282","http://www.ncbi.nlm.nih.gov/pubmed/20077788","http://www.ncbi.nlm.nih.gov/pubmed/20046005","http://www.ncbi.nlm.nih.gov/pubmed/19581773","http://www.ncbi.nlm.nih.gov/pubmed/18682429","http://www.ncbi.nlm.nih.gov/pubmed/18176362","http://www.ncbi.nlm.nih.gov/pubmed/17891917","http://www.ncbi.nlm.nih.gov/pubmed/24291968","http://www.ncbi.nlm.nih.gov/pubmed/23234677","http://www.ncbi.nlm.nih.gov/pubmed/22005151","http://www.ncbi.nlm.nih.gov/pubmed/21864038","http://www.ncbi.nlm.nih.gov/pubmed/21747144","http://www.ncbi.nlm.nih.gov/pubmed/21732154","http://www.ncbi.nlm.nih.gov/pubmed/19648687","http://www.ncbi.nlm.nih.gov/pubmed/18217186","http://www.ncbi.nlm.nih.gov/pubmed/22409941","http://www.ncbi.nlm.nih.gov/pubmed/22142810","http://www.ncbi.nlm.nih.gov/pubmed/20627738","http://www.ncbi.nlm.nih.gov/pubmed/20034896","http://www.ncbi.nlm.nih.gov/pubmed/22770539","http://www.ncbi.nlm.nih.gov/pubmed/20663605","http://www.ncbi.nlm.nih.gov/pubmed/18722676","http://www.ncbi.nlm.nih.gov/pubmed/21747139","http://www.ncbi.nlm.nih.gov/pubmed/22849994","http://www.ncbi.nlm.nih.gov/pubmed/19208478","http://www.ncbi.nlm.nih.gov/pubmed/18437526","http://www.ncbi.nlm.nih.gov/pubmed/17466337","http://www.ncbi.nlm.nih.gov/pubmed/18414352","http://www.ncbi.nlm.nih.gov/pubmed/22183934","http://www.ncbi.nlm.nih.gov/pubmed/17460154","http://www.ncbi.nlm.nih.gov/pubmed/23278581","http://www.ncbi.nlm.nih.gov/pubmed/21491460","http://www.ncbi.nlm.nih.gov/pubmed/21328260","http://www.ncbi.nlm.nih.gov/pubmed/19947039","http://www.ncbi.nlm.nih.gov/pubmed/17544450","http://www.ncbi.nlm.nih.gov/pubmed/23794683","http://www.ncbi.nlm.nih.gov/pubmed/23460475","http://www.ncbi.nlm.nih.gov/pubmed/23341732","http://www.ncbi.nlm.nih.gov/pubmed/17635211","http://www.ncbi.nlm.nih.gov/pubmed/24112993","http://www.ncbi.nlm.nih.gov/pubmed/18427534","http://www.ncbi.nlm.nih.gov/pubmed/20458068","http://www.ncbi.nlm.nih.gov/pubmed/17906603","http://www.ncbi.nlm.nih.gov/pubmed/19962870","http://www.ncbi.nlm.nih.gov/pubmed/21222577","http://www.ncbi.nlm.nih.gov/pubmed/19172815","http://www.ncbi.nlm.nih.gov/pubmed/22634638","http://www.ncbi.nlm.nih.gov/pubmed/24220173","http://www.ncbi.nlm.nih.gov/pubmed/23440963","http://www.ncbi.nlm.nih.gov/pubmed/19296376","http://www.ncbi.nlm.nih.gov/pubmed/23452772","http://www.ncbi.nlm.nih.gov/pubmed/23013366","http://www.ncbi.nlm.nih.gov/pubmed/22713949","http://www.ncbi.nlm.nih.gov/pubmed/22286807","http://www.ncbi.nlm.nih.gov/pubmed/21534375","http://www.ncbi.nlm.nih.gov/pubmed/22689834","http://www.ncbi.nlm.nih.gov/pubmed/20387102","http://www.ncbi.nlm.nih.gov/pubmed/20301347","http://www.ncbi.nlm.nih.gov/pubmed/20298126","http://www.ncbi.nlm.nih.gov/pubmed/19593127","http://www.ncbi.nlm.nih.gov/pubmed/19565307","http://www.ncbi.nlm.nih.gov/pubmed/18474849","http://www.ncbi.nlm.nih.gov/pubmed/18465647","http://www.ncbi.nlm.nih.gov/pubmed/18351523","http://www.ncbi.nlm.nih.gov/pubmed/18319533","http://www.ncbi.nlm.nih.gov/pubmed/17992264","http://www.ncbi.nlm.nih.gov/pubmed/17644292"],"snippets":[{"title":"Myasthenia gravis","conf":0.33333333333333337,"document":"http://www.ncbi.nlm.nih.gov/pubmed/17986328","text":"Disease name\nMyasthenia gravis, Autoimmune myasthenia gravis\nIncluded diseasesAutoimmune myasthenia gravis (MG) encompasses all of the immunologically-mediated disorders affecting the endplate region of the postsynaptic neuromuscular junction.","offsetInBeginSection":0,"offsetInEndSection":243,"beginSection":"sections.0","endSection":"sections.0"},{"title":"Fatigue in myasthenia gravis: is it more than muscular weakness?","conf":0.19112739302699866,"document":"http://www.ncbi.nlm.nih.gov/pubmed/24088269","text":"Our primary goal was to test the hypothesis that MG severity is associated with symptoms of autonomic disturbance, and a secondary goal was to document the prevalence of fatigue in myasthenia gravis patients","offsetInBeginSection":2999,"offsetInEndSection":3206,"beginSection":"sections.0","endSection":"sections.0"},{"title":"New Acetylcholinesterase Inhibitors for Alzheimer\u0027s Disease","conf":0.2847473987257497,"document":"http://www.ncbi.nlm.nih.gov/pubmed/22216416","text":"Inhibition of AChE was considered to be achievable as a therapeutic target because of proven efficacy of inhibition of peripheral AChE as a treatment for myasthenia gravis (MG) proving that the approach was feasible.","offsetInBeginSection":221,"offsetInEndSection":437,"beginSection":"sections.0","endSection":"sections.0"},{"title":"Current and emerging treatments for the management of myasthenia gravis","conf":0.4573295603800236,"document":"http://www.ncbi.nlm.nih.gov/pubmed/21845054","text":"Symptomatic treatment\nAcetylcholinesterase inhibitorsIn MG, the first-line option is symptomatic treatment with acetylcholinesterase inhibitors.","offsetInBeginSection":0,"offsetInEndSection":144,"beginSection":"sections.1","endSection":"sections.1"},{"title":"New treatments for myasthenia: a focus on antisense oligonucleotides","conf":0.31573481518554336,"document":"http://www.ncbi.nlm.nih.gov/pubmed/23341732","text":"AChE inhibitors were among the earliest treatment options for MG and they remain one of the most widely used drug options.4 They are used as symptomatic treatment: slowing the degradation of ACh at the NMJ, they provide a temporary improvement in muscle strength.","offsetInBeginSection":1170,"offsetInEndSection":1433,"beginSection":"sections.0","endSection":"sections.0"},{"title":"Myasthenia gravis","conf":0.31362502409359005,"document":"http://www.ncbi.nlm.nih.gov/pubmed/17986328","text":"Corticosteroids are often used as the initial immunotherapy in patients with ocular and generalized MG, particularly in patients with unsatisfactory responses to acetylcholinesterase inhibitors.","offsetInBeginSection":4017,"offsetInEndSection":4211,"beginSection":"sections.7","endSection":"sections.7"},{"title":"Fatigue in myasthenia gravis: is it more than muscular weakness?","conf":0.18609684207969418,"document":"http://www.ncbi.nlm.nih.gov/pubmed/24088269","text":"Background\nMyasthenia gravis (MG) is a chronic autoimmune disease that affects the neuromuscular junction, causing reduced muscular strength and reduced endurance of repetitive muscle use.","offsetInBeginSection":0,"offsetInEndSection":188,"beginSection":"sections.0","endSection":"sections.0"},{"title":"New Acetylcholinesterase Inhibitors for Alzheimer\u0027s Disease","conf":0.22645540682891918,"document":"http://www.ncbi.nlm.nih.gov/pubmed/22216416","text":"Compounds 1–3 and 5 have possible ChE inhibitory effects with the potential to be used for AD treatment.","offsetInBeginSection":3654,"offsetInEndSection":3758,"beginSection":"sections.3","endSection":"sections.3"},{"title":"Current and emerging treatments for the management of myasthenia gravis","conf":0.4082482904638631,"document":"http://www.ncbi.nlm.nih.gov/pubmed/21845054","text":"Other acetylcholinesterase inhibitors such as neostigmine are rarely used because of their poorer pharmacodynamic profiles and tolerability.","offsetInBeginSection":200,"offsetInEndSection":340,"beginSection":"sections.1","endSection":"sections.1"},{"title":"New treatments for myasthenia: a focus on antisense oligonucleotides","conf":0.27386127875258304,"document":"http://www.ncbi.nlm.nih.gov/pubmed/23341732","text":"The role of AChE-R in myasthenia gravis\nIn rats with experimental autoimmune myasthenia gravis (EAMG), high levels of AChE-R were found around the endplate and in serum.","offsetInBeginSection":0,"offsetInEndSection":169,"beginSection":"sections.2","endSection":"sections.2"},{"title":"Myasthenia gravis","conf":0.2946278254943948,"document":"http://www.ncbi.nlm.nih.gov/pubmed/17986328","text":"The roles for acetylcholinesterase inhibitors in MG include treatment of ocular and mild generalized disease, treatment in patients who cannot receive immune suppression, and adjunctive treatment for patients receiving immunotherapy with residual or refractory myasthenic weakness.Effective dosing of acetylcholinesterase inhibitors reduces myasthenic weakness, minimizes muscarinic medication side effects, and must be individualized to each patient\u0027s distribution of weakness and diurnal symptom fluctuation.","offsetInBeginSection":1452,"offsetInEndSection":1962,"beginSection":"sections.7","endSection":"sections.7"},{"title":"Fatigue in myasthenia gravis: is it more than muscular weakness?","conf":0.18257418583505536,"document":"http://www.ncbi.nlm.nih.gov/pubmed/24088269","text":"Our results can be used as a framework for further analysis.","offsetInBeginSection":5602,"offsetInEndSection":5662,"beginSection":"sections.3","endSection":"sections.3"},{"title":"New Acetylcholinesterase Inhibitors for Alzheimer\u0027s Disease","conf":0.20412414523193154,"document":"http://www.ncbi.nlm.nih.gov/pubmed/22216416","text":"Older Cholinesterase Inhibitors\n2.1.","offsetInBeginSection":3,"offsetInEndSection":39,"beginSection":"sections.1","endSection":"sections.1"},{"title":"Current and emerging treatments for the management of myasthenia gravis","conf":0.2461829819586655,"document":"http://www.ncbi.nlm.nih.gov/pubmed/21845054","text":"It is also noteworthy that some MuSK antibody-positive patients may show nonresponsiveness to acetylcholinesterase inhibitors.","offsetInBeginSection":1217,"offsetInEndSection":1343,"beginSection":"sections.1","endSection":"sections.1"},{"title":"New treatments for myasthenia: a focus on antisense oligonucleotides","conf":0.21081851067789195,"document":"http://www.ncbi.nlm.nih.gov/pubmed/23341732","text":"ACh inhibitors are used as adjunctive therapy in patients receiving immunomodulatory agents (such as steroids) that represent the usual long-term immunotherapy.","offsetInBeginSection":1434,"offsetInEndSection":1594,"beginSection":"sections.0","endSection":"sections.0"},{"title":"Myasthenia gravis","conf":0.2461829819586655,"document":"http://www.ncbi.nlm.nih.gov/pubmed/17986328","text":"Acetylcholinesterase inhibitors are a symptomatic therapy for MG and do not retard the underlying autoimmune attack on the neuromuscular junction.","offsetInBeginSection":1305,"offsetInEndSection":1451,"beginSection":"sections.7","endSection":"sections.7"},{"title":"Fatigue in myasthenia gravis: is it more than muscular weakness?","conf":0.13130643285972254,"document":"http://www.ncbi.nlm.nih.gov/pubmed/24088269","text":"Fifty patients (61%) used an AChEI (pyridostigmine bromide) with maximum dose 120 mg per day, and 39 patients (48%) used oral steroids.","offsetInBeginSection":798,"offsetInEndSection":933,"beginSection":"sections.2","endSection":"sections.2"},{"title":"New Acetylcholinesterase Inhibitors for Alzheimer\u0027s Disease","conf":0.20412414523193154,"document":"http://www.ncbi.nlm.nih.gov/pubmed/22216416","text":"New Cholinesterase Inhibitors\n3.1.","offsetInBeginSection":3,"offsetInEndSection":37,"beginSection":"sections.2","endSection":"sections.2"},{"title":"Current and emerging treatments for the management of myasthenia gravis","conf":0.2461829819586655,"document":"http://www.ncbi.nlm.nih.gov/pubmed/21845054","text":"Most MG patients do not achieve adequate response with acetylcholinesterase inhibitor treatment and will require further immunosuppression.","offsetInBeginSection":1077,"offsetInEndSection":1216,"beginSection":"sections.1","endSection":"sections.1"},{"title":"New treatments for myasthenia: a focus on antisense oligonucleotides","conf":0.1924500897298753,"document":"http://www.ncbi.nlm.nih.gov/pubmed/23341732","text":"Another possible indication to be investigated is their potential use in the field of some congenital myasthenia: eventually, pyridostigmine-allergic or -intolerant patients may benefit from an alternative treatment","offsetInBeginSection":572,"offsetInEndSection":787,"beginSection":"sections.5","endSection":"sections.5"},{"title":"Myasthenia gravis","conf":0.21081851067789195,"document":"http://www.ncbi.nlm.nih.gov/pubmed/17986328","text":"Acetylcholinesterase inhibitorsAcetylcholinesterase inhibitors slow the hydrolysis of acetylcholine at the neuromuscular junction and provide temporary improvement in strength in many patients with MG.","offsetInBeginSection":911,"offsetInEndSection":1112,"beginSection":"sections.7","endSection":"sections.7"},{"title":"Fatigue in myasthenia gravis: is it more than muscular weakness?","conf":0.11785113019775793,"document":"http://www.ncbi.nlm.nih.gov/pubmed/24088269","text":"However, this questionnaire provides a screening tool for patients with MG, and objective physiological tests should be used in further studies.","offsetInBeginSection":4951,"offsetInEndSection":5095,"beginSection":"sections.3","endSection":"sections.3"},{"title":"New Acetylcholinesterase Inhibitors for Alzheimer\u0027s Disease","conf":0.18257418583505536,"document":"http://www.ncbi.nlm.nih.gov/pubmed/22216416","text":"The first three are AChE inhibitors and memantine is not.","offsetInBeginSection":825,"offsetInEndSection":882,"beginSection":"sections.0","endSection":"sections.0"},{"title":"Current and emerging treatments for the management of myasthenia gravis","conf":0.22645540682891918,"document":"http://www.ncbi.nlm.nih.gov/pubmed/21845054","text":"Introduction\nMyasthenia gravis (MG) is a neuromuscular disorder characterized by a clinical course of fluctuating, painless muscle weakness.","offsetInBeginSection":0,"offsetInEndSection":140,"beginSection":"sections.0","endSection":"sections.0"},{"title":"New treatments for myasthenia: a focus on antisense oligonucleotides","conf":0.1684303842133038,"document":"http://www.ncbi.nlm.nih.gov/pubmed/23341732","text":"We did a systematic PubMed search using the search terms “myasthenia gravis” and “antisense oligonucleotides” and appropriate citations were manually selected from the search results for inclusion in this review","offsetInBeginSection":1715,"offsetInEndSection":1926,"beginSection":"sections.0","endSection":"sections.0"},{"title":"Myasthenia gravis","conf":0.20254787341673333,"document":"http://www.ncbi.nlm.nih.gov/pubmed/17986328","text":"Although acetylcholinesterase inhibitors were among the earliest and remain one of the most widely prescribed treatments for MG, there are no controlled clinical trials of these agents in MG.","offsetInBeginSection":1113,"offsetInEndSection":1304,"beginSection":"sections.7","endSection":"sections.7"},{"title":"Fatigue in myasthenia gravis: is it more than muscular weakness?","conf":0.11754541987684669,"document":"http://www.ncbi.nlm.nih.gov/pubmed/24088269","text":"Substantial fatigue or “fatigue caseness” was defined as a sum score of dichotomised responses ≥ 4 and chronic fatigue was defined as a sum score of dichotomised responses ≥ 4 and symptom duration of ≥ 6 months [16].The Myasthenia Gravis Questionnaire (MGQ) is a 25-item, disease-specific, patient-reported questionnaire [18,19].","offsetInBeginSection":3227,"offsetInEndSection":3556,"beginSection":"sections.1","endSection":"sections.1"},{"title":"New Acetylcholinesterase Inhibitors for Alzheimer\u0027s Disease","conf":0.1543033499620919,"document":"http://www.ncbi.nlm.nih.gov/pubmed/22216416","text":"DonepezilDonepezil was approved in 1996 for the treatment of mild-to-moderate AD.","offsetInBeginSection":1647,"offsetInEndSection":1728,"beginSection":"sections.1","endSection":"sections.1"},{"title":"Current and emerging treatments for the management of myasthenia gravis","conf":0.18257418583505536,"document":"http://www.ncbi.nlm.nih.gov/pubmed/21845054","text":"Pyridostigmine bromide is the most commonly used drug.","offsetInBeginSection":145,"offsetInEndSection":199,"beginSection":"sections.1","endSection":"sections.1"},{"title":"New treatments for myasthenia: a focus on antisense oligonucleotides","conf":0.15294382258037453,"document":"http://www.ncbi.nlm.nih.gov/pubmed/23341732","text":"Inclusion criteria for the study were the following: MG with class II or higher-stage disease based on Myasthenia Gravis Foundation of America (MGFA) classification; and ACh-R-positive patients or patients with a clearly evident EMG neuromuscular function study.","offsetInBeginSection":1509,"offsetInEndSection":1771,"beginSection":"sections.3","endSection":"sections.3"},{"title":"Myasthenia gravis","conf":0.17407765595569785,"document":"http://www.ncbi.nlm.nih.gov/pubmed/17986328","text":"There must be adequate immobilization of the stimulating and recording electrodes, delivery of supramaximal stimuli, muscle warming to 35°C, and withholding of acetylcholinesterase inhibitors for at least 12 hours prior to testing.","offsetInBeginSection":3303,"offsetInEndSection":3534,"beginSection":"sections.5","endSection":"sections.5"},{"title":"Fatigue in myasthenia gravis: is it more than muscular weakness?","conf":0.11215443081840887,"document":"http://www.ncbi.nlm.nih.gov/pubmed/24088269","text":"The authors used the validated Swedish version [19], translating only a few terms into Norwegian (which is very similar to Swedish).","offsetInBeginSection":3557,"offsetInEndSection":3689,"beginSection":"sections.1","endSection":"sections.1"},{"title":"New Acetylcholinesterase Inhibitors for Alzheimer\u0027s Disease","conf":0.1543033499620919,"document":"http://www.ncbi.nlm.nih.gov/pubmed/22216416","text":"All of the new hybrids have proven to be highly potent hAChE inhibitors.","offsetInBeginSection":4228,"offsetInEndSection":4300,"beginSection":"sections.4","endSection":"sections.4"},{"title":"Current and emerging treatments for the management of myasthenia gravis","conf":0.15713484026367722,"document":"http://www.ncbi.nlm.nih.gov/pubmed/21845054","text":"In one study, 71% of MuSK antibody positive patients failed to respond to acetylcholinesterase inhibitors, compared to 18% respectively of AChR antibody positive and seronegative patients.8 Pyridostigmine is generally well tolerated.","offsetInBeginSection":1344,"offsetInEndSection":1577,"beginSection":"sections.1","endSection":"sections.1"},{"title":"New treatments for myasthenia: a focus on antisense oligonucleotides","conf":0.14433756729740646,"document":"http://www.ncbi.nlm.nih.gov/pubmed/23341732","text":"More than 90% of the patients felt an improvement in symptoms during the treatment period.","offsetInBeginSection":3019,"offsetInEndSection":3109,"beginSection":"sections.3","endSection":"sections.3"},{"title":"Myasthenia gravis","conf":0.16666666666666669,"document":"http://www.ncbi.nlm.nih.gov/pubmed/17986328","text":"Management\nTreatment must be individualized to each patient with MG.","offsetInBeginSection":0,"offsetInEndSection":68,"beginSection":"sections.7","endSection":"sections.7"},{"title":"Fatigue in myasthenia gravis: is it more than muscular weakness?","conf":0.10186331473967244,"document":"http://www.ncbi.nlm.nih.gov/pubmed/24088269","text":"Figure 2 illustrates the difference in fatigue levels and the prevalence of fatigue caseness and chronic fatigue among MG patients and controls.Figure 2Fatigue score and the prevalence of fatigue caseness and chronic fatigue among myasthenia gravis patients and controls.Bivariate and multivariate analysisOf the explanatory variables in Level 1 (Figure 1), no independent associations with fatigue level were found for patients’ age, gender, BMI, disease duration, physical activity or smoking.","offsetInBeginSection":2177,"offsetInEndSection":2672,"beginSection":"sections.2","endSection":"sections.2"},{"title":"New Acetylcholinesterase Inhibitors for Alzheimer\u0027s Disease","conf":0.14433756729740646,"document":"http://www.ncbi.nlm.nih.gov/pubmed/22216416","text":"Galantamine was approved for the treatment of mild-to-moderate AD in February 2001.","offsetInBeginSection":5068,"offsetInEndSection":5151,"beginSection":"sections.1","endSection":"sections.1"},{"title":"Current and emerging treatments for the management of myasthenia gravis","conf":0.1543033499620919,"document":"http://www.ncbi.nlm.nih.gov/pubmed/21845054","text":"Oral prednisolone is the most commonly used first-line drug.","offsetInBeginSection":1752,"offsetInEndSection":1812,"beginSection":"sections.2","endSection":"sections.2"},{"title":"New treatments for myasthenia: a focus on antisense oligonucleotides","conf":0.13703774196550636,"document":"http://www.ncbi.nlm.nih.gov/pubmed/23341732","text":"The failure of AChE inhibitors in blocking AChE-R overexpression, thus preventing its muscle-weakening effects, may be due to their inefficiency to distinguish between the two AChE isoforms.17 Suppressing the AChE-R overexpression by targeting AChE pre-mRNA is an alternative in the treatment of MG","offsetInBeginSection":732,"offsetInEndSection":1030,"beginSection":"sections.2","endSection":"sections.2"},{"title":"Myasthenia gravis","conf":0.14433756729740646,"document":"http://www.ncbi.nlm.nih.gov/pubmed/17986328","text":"These dose dependent and self-limited side effects may be treated with glycopyrrolate, and the gastrointestinal side effects may be treated with diphenoxylate hydrochloride with atropine or loperamide hydrochloride.Cholinergic crisis may develop with excessive dosing of acetylcholinesterase inhibitors in patients with more severe MG.","offsetInBeginSection":3002,"offsetInEndSection":3337,"beginSection":"sections.7","endSection":"sections.7"},{"title":"New Acetylcholinesterase Inhibitors for Alzheimer\u0027s Disease","conf":0.1421338109037403,"document":"http://www.ncbi.nlm.nih.gov/pubmed/22216416","text":"Physostigmine (Eserine)Physostigmine was the first ChEI investigated for the treatment of AD.","offsetInBeginSection":40,"offsetInEndSection":133,"beginSection":"sections.1","endSection":"sections.1"},{"title":"Current and emerging treatments for the management of myasthenia gravis","conf":0.13900960937138318,"document":"http://www.ncbi.nlm.nih.gov/pubmed/21845054","text":"In MG, the concentration of AChR and MuSK antibodies has been shown to decrease with plasma exchange.74,75 Plasma exchange was first used in the 1970s in MG.76 Several relatively large open studies of 20 or more patients, most of whom were already on other immunosuppressive or immunomodulatory treatment, have shown benefit from plasma exchange.","offsetInBeginSection":3569,"offsetInEndSection":3915,"beginSection":"sections.4","endSection":"sections.4"},{"title":"New treatments for myasthenia: a focus on antisense oligonucleotides","conf":0.13608276348795434,"document":"http://www.ncbi.nlm.nih.gov/pubmed/23341732","text":"Steroids treatment was continued during the whole period, while pyridostigmine was suspended and reintroduced when it was required.","offsetInBeginSection":2272,"offsetInEndSection":2403,"beginSection":"sections.3","endSection":"sections.3"},{"title":"Myasthenia gravis","conf":0.14159846508095775,"document":"http://www.ncbi.nlm.nih.gov/pubmed/17986328","text":"Peak improvement is usually observed at about 45 minutes after ingestion, and benefits may last four hours or more.The most salient side effects of acetylcholinesterase inhibitors relate to increased muscarinic activity and include nausea, vomiting, abdominal cramping, diarrhea, diaphoresis, and increased lacrimation, salivation, and bronchial secretions.","offsetInBeginSection":2644,"offsetInEndSection":3001,"beginSection":"sections.7","endSection":"sections.7"},{"title":"New Acetylcholinesterase Inhibitors for Alzheimer\u0027s Disease","conf":0.13608276348795434,"document":"http://www.ncbi.nlm.nih.gov/pubmed/22216416","text":"Before tacrine, physostigmine, the classic AChE inhibitor (AChEI) was investigated as a treatment for AD.","offsetInBeginSection":542,"offsetInEndSection":647,"beginSection":"sections.0","endSection":"sections.0"},{"title":"Current and emerging treatments for the management of myasthenia gravis","conf":0.13608276348795434,"document":"http://www.ncbi.nlm.nih.gov/pubmed/21845054","text":"Conclusion\nThere remain major gaps in our knowledge of the treatments used in generalized MG.","offsetInBeginSection":0,"offsetInEndSection":93,"beginSection":"sections.7","endSection":"sections.7"},{"title":"New treatments for myasthenia: a focus on antisense oligonucleotides","conf":0.12712834523274566,"document":"http://www.ncbi.nlm.nih.gov/pubmed/23341732","text":"AChE-R accumulation in serum of EAMG and myasthenic patients may be the consequence of the imbalance between ACh and AChRs, with ACh prevailing on the number of receptors, as it occurs under treatment with AChE inhibitors.12 Slowing ACh catalysis results in an increased AChE-R production, due to a rapid feedback induction of AChE-R pre-mRNA.","offsetInBeginSection":170,"offsetInEndSection":513,"beginSection":"sections.2","endSection":"sections.2"},{"title":"Myasthenia gravis","conf":0.13608276348795434,"document":"http://www.ncbi.nlm.nih.gov/pubmed/17986328","text":"When beginning corticosteroid treatment in such patients, strength and respiratory function should be closely monitored.","offsetInBeginSection":8087,"offsetInEndSection":8207,"beginSection":"sections.7","endSection":"sections.7"},{"title":"New Acetylcholinesterase Inhibitors for Alzheimer\u0027s Disease","conf":0.13608276348795434,"document":"http://www.ncbi.nlm.nih.gov/pubmed/22216416","text":"MetrifonateMetrifonate is a long-acting irreversible ChEI that was originally used to treat schistosomiasis.","offsetInBeginSection":6194,"offsetInEndSection":6302,"beginSection":"sections.1","endSection":"sections.1"},{"title":"Current and emerging treatments for the management of myasthenia gravis","conf":0.12909944487358058,"document":"http://www.ncbi.nlm.nih.gov/pubmed/21845054","text":"If there is such a concern, cholinesterase inhibitors need to be temporarily withdrawn and the patient carefully monitored for improvement","offsetInBeginSection":2201,"offsetInEndSection":2339,"beginSection":"sections.1","endSection":"sections.1"},{"title":"New treatments for myasthenia: a focus on antisense oligonucleotides","conf":0.12309149097933275,"document":"http://www.ncbi.nlm.nih.gov/pubmed/23341732","text":"In this review, we present a summary of current treatment progresses in managing MG, regarding the symptomatic therapy.","offsetInBeginSection":1595,"offsetInEndSection":1714,"beginSection":"sections.0","endSection":"sections.0"},{"title":"Myasthenia gravis","conf":0.13608276348795434,"document":"http://www.ncbi.nlm.nih.gov/pubmed/17986328","text":"Serum electrolytes, glucose, blood pressure, and weight are monitored periodically during treatment.","offsetInBeginSection":7130,"offsetInEndSection":7230,"beginSection":"sections.7","endSection":"sections.7"},{"title":"New Acetylcholinesterase Inhibitors for Alzheimer\u0027s Disease","conf":0.1342312110428049,"document":"http://www.ncbi.nlm.nih.gov/pubmed/22216416","text":"BuCh is a synthetic compound used to distinguish AChE receptors from BuChE receptors.","offsetInBeginSection":1224,"offsetInEndSection":1309,"beginSection":"sections.0","endSection":"sections.0"},{"title":"Current and emerging treatments for the management of myasthenia gravis","conf":0.12331590591674754,"document":"http://www.ncbi.nlm.nih.gov/pubmed/21845054","text":"However, methotrexate is still often used as second-line treatment in patients who do not tolerate or are unresponsive to azathioprine for several reasons: (a) data extrapolated from other autoimmune disorders suggest that it should be effective in MG,20 (b) expert panel guidelines support its use as second-line treatment in MG,20 and (c) many physicians have extensive personal experience of successfully using it in MG.21 A clinical trial to assess the efficacy of methotrexate in MG is underway.Adverse events associated with methotrexate are usually mild such as alopecia, mucositis, gastrointestinal intolerance, and mild elevation of liver enzymes.","offsetInBeginSection":6196,"offsetInEndSection":6852,"beginSection":"sections.3","endSection":"sections.3"},{"title":"New treatments for myasthenia: a focus on antisense oligonucleotides","conf":0.12309149097933275,"document":"http://www.ncbi.nlm.nih.gov/pubmed/23341732","text":"Figure 1 shows the role of AChE-R, its mechanism of action and its interferences by antisense treatment.","offsetInBeginSection":407,"offsetInEndSection":511,"beginSection":"sections.3","endSection":"sections.3"},{"title":"Myasthenia gravis","conf":0.12909944487358058,"document":"http://www.ncbi.nlm.nih.gov/pubmed/17986328","text":"In light of this, cyclosporine is used in MG as a steroid-sparing agent or for refractory generalized disease.","offsetInBeginSection":11455,"offsetInEndSection":11565,"beginSection":"sections.7","endSection":"sections.7"},{"title":"New Acetylcholinesterase Inhibitors for Alzheimer\u0027s Disease","conf":0.12909944487358058,"document":"http://www.ncbi.nlm.nih.gov/pubmed/22216416","text":"Four drugs are currently available for AD treatment: galantamine, rivastigmine, donepezil, and memantine.","offsetInBeginSection":719,"offsetInEndSection":824,"beginSection":"sections.0","endSection":"sections.0"},{"title":"Current and emerging treatments for the management of myasthenia gravis","conf":0.11322770341445959,"document":"http://www.ncbi.nlm.nih.gov/pubmed/21845054","text":"This steroid dip usually occurs 4 to 10 days after starting treatment and may precipitate a MG crisis.","offsetInBeginSection":2097,"offsetInEndSection":2199,"beginSection":"sections.2","endSection":"sections.2"},{"title":"New treatments for myasthenia: a focus on antisense oligonucleotides","conf":0.12126781251816651,"document":"http://www.ncbi.nlm.nih.gov/pubmed/23341732","text":"This leads to an increased ACh degradation and a subsequent limitation of the efficacy of AChE inhibitors.16 The effect of AChE inhibitors is actually short lasting, requiring oral drug administration every 4–6 hours.","offsetInBeginSection":514,"offsetInEndSection":731,"beginSection":"sections.2","endSection":"sections.2"},{"title":"Myasthenia gravis","conf":0.11785113019775793,"document":"http://www.ncbi.nlm.nih.gov/pubmed/17986328","text":"A detailed review of treatment issues in autoimmune MG may be found elsewhere [38].","offsetInBeginSection":827,"offsetInEndSection":910,"beginSection":"sections.7","endSection":"sections.7"},{"title":"New Acetylcholinesterase Inhibitors for Alzheimer\u0027s Disease","conf":0.12909944487358058,"document":"http://www.ncbi.nlm.nih.gov/pubmed/22216416","text":"Many of the drugs that are available for treatment of AD target both AChE and BuChE, but some are more selective than others.","offsetInBeginSection":1310,"offsetInEndSection":1435,"beginSection":"sections.0","endSection":"sections.0"},{"title":"Current and emerging treatments for the management of myasthenia gravis","conf":0.11322770341445959,"document":"http://www.ncbi.nlm.nih.gov/pubmed/21845054","text":"Much of the evidence that we use in determining the choice of treatment derives from clinical experience, observational studies, and expert opinion.","offsetInBeginSection":94,"offsetInEndSection":242,"beginSection":"sections.7","endSection":"sections.7"},{"title":"New treatments for myasthenia: a focus on antisense oligonucleotides","conf":0.11664236870396087,"document":"http://www.ncbi.nlm.nih.gov/pubmed/23341732","text":"Introduction\nMyasthenia gravis (MG) is an autoimmune disorder caused by autoantibodies binding to the nicotinic acetylcholine receptor (nAChR) on the postsynaptic membrane at the neuromuscular junction (NMJ),1 or, less frequently, to a muscle-specific tyrosine kinase (MuSK), an AChR-associated protein involved in clustering of AChRs and expressed in mature NMJ.2 In MG, the binding of autoantibodies to AChRs or MuSK results in an abnormal neuromuscular transmission and muscle weakness.","offsetInBeginSection":0,"offsetInEndSection":489,"beginSection":"sections.0","endSection":"sections.0"},{"title":"Myasthenia gravis","conf":0.11785113019775793,"document":"http://www.ncbi.nlm.nih.gov/pubmed/17986328","text":"Higher doses are associated with myelosuppression, and periodic blood counts are performed during treatment as surveillance against leukopenia or anemia.","offsetInBeginSection":14709,"offsetInEndSection":14862,"beginSection":"sections.7","endSection":"sections.7"},{"title":"New Acetylcholinesterase Inhibitors for Alzheimer\u0027s Disease","conf":0.12909944487358058,"document":"http://www.ncbi.nlm.nih.gov/pubmed/22216416","text":"Metrifonate is not an approved AD treatment but shows efficacy that was outweighed by safety risks.2.7.","offsetInBeginSection":6839,"offsetInEndSection":6942,"beginSection":"sections.1","endSection":"sections.1"},{"title":"Current and emerging treatments for the management of myasthenia gravis","conf":0.11215443081840887,"document":"http://www.ncbi.nlm.nih.gov/pubmed/21845054","text":"Corticosteroids are usually used as an interim measure while titrating up the doses of other immunosuppressants and waiting for those immunosuppressants to take full effect.","offsetInBeginSection":1813,"offsetInEndSection":1986,"beginSection":"sections.2","endSection":"sections.2"},{"title":"Myasthenia gravis","conf":0.11322770341445959,"document":"http://www.ncbi.nlm.nih.gov/pubmed/17986328","text":"In post-menopausal women, a baseline bone density evaluation is performed and repeated every six months during treatment.","offsetInBeginSection":7327,"offsetInEndSection":7448,"beginSection":"sections.7","endSection":"sections.7"},{"title":"New Acetylcholinesterase Inhibitors for Alzheimer\u0027s Disease","conf":0.12909944487358058,"document":"http://www.ncbi.nlm.nih.gov/pubmed/22216416","text":"TacrineTacrine was the first drug approved for treatment of AD in 1993 [2].","offsetInBeginSection":711,"offsetInEndSection":786,"beginSection":"sections.1","endSection":"sections.1"},{"title":"Current and emerging treatments for the management of myasthenia gravis","conf":0.1091089451179962,"document":"http://www.ncbi.nlm.nih.gov/pubmed/21845054","text":"The most widely used models nowadays are rodents, and active immunization is with AChR from Torpedo electric organ which is a rich source of the receptor.","offsetInBeginSection":290,"offsetInEndSection":444,"beginSection":"sections.6","endSection":"sections.6"},{"title":"Myasthenia gravis","conf":0.11322770341445959,"document":"http://www.ncbi.nlm.nih.gov/pubmed/17986328","text":"Whether corticosteroid treatment begun early in the course of ocular MG can prevent generalization has yet to be demonstrated.","offsetInBeginSection":621,"offsetInEndSection":747,"beginSection":"sections.9","endSection":"sections.9"},{"title":"New Acetylcholinesterase Inhibitors for Alzheimer\u0027s Disease","conf":0.12909944487358058,"document":"http://www.ncbi.nlm.nih.gov/pubmed/22216416","text":"Both of the treatment groups showed significant improvement in the behavioral, cognitive, and functional symptoms of AD.","offsetInBeginSection":5603,"offsetInEndSection":5723,"beginSection":"sections.1","endSection":"sections.1"},{"title":"Current and emerging treatments for the management of myasthenia gravis","conf":0.10540925533894598,"document":"http://www.ncbi.nlm.nih.gov/pubmed/21845054","text":"The choice between plasma exchange and intravenous immunoglobulin is often based on the physician’s opinion of the ability of a patient to tolerate each treatment.","offsetInBeginSection":5195,"offsetInEndSection":5358,"beginSection":"sections.4","endSection":"sections.4"},{"title":"Myasthenia gravis","conf":0.11134044285378084,"document":"http://www.ncbi.nlm.nih.gov/pubmed/17986328","text":"Factors to be considered in selecting treatment include the distribution, duration, and severity of myasthenic weakness and functional impairment, the risk for treatment complications related to medical comorbidities, age, and gender, and the ability of the patient to obtain medication and comply with drug dosing schedules and toxicity monitoring.","offsetInBeginSection":288,"offsetInEndSection":637,"beginSection":"sections.7","endSection":"sections.7"},{"title":"New Acetylcholinesterase Inhibitors for Alzheimer\u0027s Disease","conf":0.12909944487358058,"document":"http://www.ncbi.nlm.nih.gov/pubmed/22216416","text":"Discontinuation of treatment due to adverse effects was minimal in both groups and equal to the placebo group.","offsetInBeginSection":5492,"offsetInEndSection":5602,"beginSection":"sections.1","endSection":"sections.1"},{"title":"Current and emerging treatments for the management of myasthenia gravis","conf":0.10502100630210075,"document":"http://www.ncbi.nlm.nih.gov/pubmed/21845054","text":"In the past 70 years, treatment advances have reduced the mortality of MG from 70% between 1915 and 19341 to 5% or less now.4\nIn this review an overview will be given of the mechanism, evidence, indication, and relevant adverse effect profile of the different treatment options in generalized MG.","offsetInBeginSection":1408,"offsetInEndSection":1704,"beginSection":"sections.0","endSection":"sections.0"},{"title":"Myasthenia gravis","conf":0.10814761408717503,"document":"http://www.ncbi.nlm.nih.gov/pubmed/17986328","text":"Epidemiology\nAlthough MG is rare, prevalence rates for MG have increased over time, likely due to improvements in diagnosis and treatment.","offsetInBeginSection":0,"offsetInEndSection":138,"beginSection":"sections.2","endSection":"sections.2"},{"title":"New Acetylcholinesterase Inhibitors for Alzheimer\u0027s Disease","conf":0.12909944487358058,"document":"http://www.ncbi.nlm.nih.gov/pubmed/22216416","text":"The primary effect would be as an AChE inhibitor rather than as BACE1 inhibitors [19].","offsetInBeginSection":3759,"offsetInEndSection":3845,"beginSection":"sections.3","endSection":"sections.3"},{"title":"Current and emerging treatments for the management of myasthenia gravis","conf":0.10206207261596577,"document":"http://www.ncbi.nlm.nih.gov/pubmed/21845054","text":"Progressive multifocal leukoencephalopathy has been associated with mycophenolate mofetil treatment.RituximabRituximab is a chimeric monoclonal antibody against the B-cell surface marker CD20.","offsetInBeginSection":9730,"offsetInEndSection":9922,"beginSection":"sections.3","endSection":"sections.3"},{"title":"Myasthenia gravis","conf":0.10741723110591495,"document":"http://www.ncbi.nlm.nih.gov/pubmed/17986328","text":"Before initiating treatment with corticosteroids or any long-term immunotherapy, PPD testing should be considered as a screen for tuberculosis.Corticosteroid-related MG exacerbations may produce transient but potentially serious increases in myasthenic weakness in up to 15% of patients beginning treatment with corticosteroids [40].","offsetInBeginSection":7449,"offsetInEndSection":7782,"beginSection":"sections.7","endSection":"sections.7"},{"title":"New Acetylcholinesterase Inhibitors for Alzheimer\u0027s Disease","conf":0.12909944487358058,"document":"http://www.ncbi.nlm.nih.gov/pubmed/22216416","text":"Flavonoids have been of great interest in AD research and treatment because of their free radical scavenging properties.","offsetInBeginSection":4813,"offsetInEndSection":4933,"beginSection":"sections.3","endSection":"sections.3"},{"title":"Current and emerging treatments for the management of myasthenia gravis","conf":0.10127393670836667,"document":"http://www.ncbi.nlm.nih.gov/pubmed/21845054","text":"Various studies in experimental models of MG aim to develop novel and improved treatments that would have less adverse events than currently used treatments.","offsetInBeginSection":955,"offsetInEndSection":1112,"beginSection":"sections.7","endSection":"sections.7"},{"title":"Myasthenia gravis","conf":0.10540925533894598,"document":"http://www.ncbi.nlm.nih.gov/pubmed/17986328","text":"Patients with ryanodine antibodies may exhibit severe, treatment-resistant MG associated with malignant thymomas [34].","offsetInBeginSection":9006,"offsetInEndSection":9124,"beginSection":"sections.5","endSection":"sections.5"},{"title":"New Acetylcholinesterase Inhibitors for Alzheimer\u0027s Disease","conf":0.11785113019775793,"document":"http://www.ncbi.nlm.nih.gov/pubmed/22216416","text":"Ladostigil treatment had no effect on memory, glial, or proNGF immunoreactivity in young rats [32].","offsetInBeginSection":2619,"offsetInEndSection":2718,"beginSection":"sections.5","endSection":"sections.5"},{"title":"Myasthenia gravis","conf":0.10540925533894598,"document":"http://www.ncbi.nlm.nih.gov/pubmed/17986328","text":"However, the typically long delay of four to eight months from beginning treatment with azathioprine to improved strength in MG is a significant liability to its usefulness, particularly in MG patients with progressive disease or functionally limiting symptoms.In a prospective, randomized, double-blind study comparing prednisolone with prednisolone plus azathioprine, the prednisolone plus azathioprine treatment group exhibited longer remissions, fewer treatment failures, fewer side effects, and reduced maintenance doses of prednisolone [46].","offsetInBeginSection":9210,"offsetInEndSection":9757,"beginSection":"sections.7","endSection":"sections.7"},{"title":"New Acetylcholinesterase Inhibitors for Alzheimer\u0027s Disease","conf":0.11322770341445959,"document":"http://www.ncbi.nlm.nih.gov/pubmed/22216416","text":"In addition, patients who used the drug required periodic blood monitoring due to hepatotoxicity [4].","offsetInBeginSection":1312,"offsetInEndSection":1413,"beginSection":"sections.1","endSection":"sections.1"},{"title":"Myasthenia gravis","conf":0.10425720702853739,"document":"http://www.ncbi.nlm.nih.gov/pubmed/17986328","text":"PEX is generally reserved for short-term treatment to achieve rapid strength improvement in myasthenic exacerbations or crises, to prepare patients for thymectomy or another surgical procedure, to prevent steroid-related MG exacerbations in susceptible patients beginning corticosteroid treatment, and for rare patients refractory to all other treatments.","offsetInBeginSection":15729,"offsetInEndSection":16084,"beginSection":"sections.7","endSection":"sections.7"},{"title":"New Acetylcholinesterase Inhibitors for Alzheimer\u0027s Disease","conf":0.11322770341445959,"document":"http://www.ncbi.nlm.nih.gov/pubmed/22216416","text":"Since it is marketed in the US as a nutraceutical supplement because it lacks a proprietary patent for the treatment of AD, FDA approval is not being pursued.","offsetInBeginSection":1775,"offsetInEndSection":1933,"beginSection":"sections.3","endSection":"sections.3"},{"title":"Myasthenia gravis","conf":0.10206207261596577,"document":"http://www.ncbi.nlm.nih.gov/pubmed/17986328","text":"Given a paucity of side effects, MMF is used in MG both as a steroid-sparing agent and as initial immunotherapy in patients at risk for corticosteroid complications.","offsetInBeginSection":13700,"offsetInEndSection":13865,"beginSection":"sections.7","endSection":"sections.7"},{"title":"New Acetylcholinesterase Inhibitors for Alzheimer\u0027s Disease","conf":0.11322770341445959,"document":"http://www.ncbi.nlm.nih.gov/pubmed/22216416","text":"The study concluded that the most promising candidates to the development of AChEI for AD treatment were derived from cardanol [22].","offsetInBeginSection":6011,"offsetInEndSection":6143,"beginSection":"sections.3","endSection":"sections.3"},{"title":"New Acetylcholinesterase Inhibitors for Alzheimer\u0027s Disease","conf":0.11322770341445959,"document":"http://www.ncbi.nlm.nih.gov/pubmed/22216416","text":"With all the properties that these hybrids possess, it could be a possible therapeutic drug treatment in vivo as well [3].5.6.","offsetInBeginSection":5971,"offsetInEndSection":6097,"beginSection":"sections.4","endSection":"sections.4"},{"title":"New Acetylcholinesterase Inhibitors for Alzheimer\u0027s Disease","conf":0.11322770341445959,"document":"http://www.ncbi.nlm.nih.gov/pubmed/22216416","text":"The synthetic analogues have only been tested in vitro at this time, but it is an area that can help direct future treatment options for AD.","offsetInBeginSection":873,"offsetInEndSection":1013,"beginSection":"sections.6","endSection":"sections.6"},{"title":"New Acetylcholinesterase Inhibitors for Alzheimer\u0027s Disease","conf":0.11215443081840887,"document":"http://www.ncbi.nlm.nih.gov/pubmed/22216416","text":"But, until the relationship between metrifonate and neuromuscular dysfunction is further explored, metrifonate is not an option for AD treatment at this time [11].","offsetInBeginSection":6675,"offsetInEndSection":6838,"beginSection":"sections.1","endSection":"sections.1"},{"title":"New Acetylcholinesterase Inhibitors for Alzheimer\u0027s Disease","conf":0.1091089451179962,"document":"http://www.ncbi.nlm.nih.gov/pubmed/22216416","text":"Rivastigmine was approved for the treatment of mild-to-moderate AD in 2000 and has since gained approval for Parkinson\u0027s related dementias.","offsetInBeginSection":3598,"offsetInEndSection":3737,"beginSection":"sections.1","endSection":"sections.1"},{"title":"New Acetylcholinesterase Inhibitors for Alzheimer\u0027s Disease","conf":0.1091089451179962,"document":"http://www.ncbi.nlm.nih.gov/pubmed/22216416","text":"Peak effect of inhibiting acetylcholinesterase was achieved about one hour after a single oral dose of 8 mg in some healthy volunteers.","offsetInBeginSection":6002,"offsetInEndSection":6137,"beginSection":"sections.1","endSection":"sections.1"},{"title":"New Acetylcholinesterase Inhibitors for Alzheimer\u0027s Disease","conf":0.1091089451179962,"document":"http://www.ncbi.nlm.nih.gov/pubmed/22216416","text":"Huperzine AHuperzine A (HupA) is a Lycopodium alkaloid isolated from the Chinese medicinal herb Huperzia  serrata used for memory deficiency.","offsetInBeginSection":26,"offsetInEndSection":167,"beginSection":"sections.3","endSection":"sections.3"},{"title":"New Acetylcholinesterase Inhibitors for Alzheimer\u0027s Disease","conf":0.1091089451179962,"document":"http://www.ncbi.nlm.nih.gov/pubmed/22216416","text":"Nevertheless, this suggests that galangin could be developed as a potential treatment for AD because of the dual MOA of ChEI and free radical scavenging properties.","offsetInBeginSection":5304,"offsetInEndSection":5468,"beginSection":"sections.3","endSection":"sections.3"}],"concepts":["http://www.disease-ontology.org/api/metadata/DOID:437","http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field\u003duid\u0026exact\u003dFind+Exact+Term\u0026term\u003dD009157","http://www.disease-ontology.org/api/metadata/DOID:14043","http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field\u003duid\u0026exact\u003dFind+Exact+Term\u0026term\u003dD020941","http://www.uniprot.org/uniprot/ACES_NAJOX","http://www.uniprot.org/uniprot/ACES_BOVIN","http://www.uniprot.org/uniprot/ACES_DANRE","http://www.uniprot.org/uniprot/ACES_FELCA","http://www.uniprot.org/uniprot/ACES_CULPP","http://www.uniprot.org/uniprot/ACES_CULTO","http://www.uniprot.org/uniprot/ACES_LEPDE","http://www.uniprot.org/uniprot/ACES_HUMAN","http://www.uniprot.org/uniprot/ACES_BUNFA","http://www.uniprot.org/uniprot/ACES_MOUSE","http://www.uniprot.org/uniprot/ACES_DROME","http://www.uniprot.org/uniprot/ACES_CHICK","http://www.uniprot.org/uniprot/ACES_TORMA","http://www.uniprot.org/uniprot/ACES_RABIT","http://www.uniprot.org/uniprot/ACES_ELEEL","http://www.uniprot.org/uniprot/ACES_CULPI","http://www.uniprot.org/uniprot/ACES_ANOGA","http://www.uniprot.org/uniprot/ACES_CULQU","http://www.uniprot.org/uniprot/ACES_ANOST","http://www.uniprot.org/uniprot/ACES_TORCA","http://www.uniprot.org/uniprot/ACES_RAT","http://www.uniprot.org/uniprot/ACES_MYXGL","http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field\u003duid\u0026exact\u003dFind+Exact+Term\u0026term\u003dD020720","http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field\u003duid\u0026exact\u003dFind+Exact+Term\u0026term\u003dD000110","http://www.uniprot.org/uniprot/ACE1_CAEEL","http://www.uniprot.org/uniprot/ACE1_CAEBR","http://www.uniprot.org/uniprot/ACE4_CAEBR","http://amigo.geneontology.org/cgi-bin/amigo/term_details?term\u003dGO:0003990","http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field\u003duid\u0026exact\u003dFind+Exact+Term\u0026term\u003dD002800","http://www.uniprot.org/uniprot/AKA12_HUMAN","http://www.uniprot.org/uniprot/DISI1_GLOUS","http://www.uniprot.org/uniprot/DISI2_GLOUS","http://www.uniprot.org/uniprot/RNAS2_AOTTR","http://www.uniprot.org/uniprot/RNAS2_NOMLE","http://www.uniprot.org/uniprot/RNAS2_SAGLB","http://www.uniprot.org/uniprot/RNAS2_PAPHA","http://www.uniprot.org/uniprot/RNAS2_GORGO","http://www.uniprot.org/uniprot/RNAS2_CHLAE","http://www.uniprot.org/uniprot/RNAS2_CALJA","http://www.uniprot.org/uniprot/RNAS2_SAISC","http://www.uniprot.org/uniprot/RNAS2_MACNE","http://www.uniprot.org/uniprot/RNAS2_HUMAN","http://www.uniprot.org/uniprot/RNAS2_PANTR","http://www.uniprot.org/uniprot/RNAS2_MACFA","http://www.uniprot.org/uniprot/RNAS2_SAGOE","http://www.uniprot.org/uniprot/RNAS2_PONPY","http://www.uniprot.org/uniprot/CUTA_HUMAN","http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field\u003duid\u0026exact\u003dFind+Exact+Term\u0026term\u003dD020294","http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field\u003duid\u0026exact\u003dFind+Exact+Term\u0026term\u003dD013812"],"triples":[{"s":"http://linkedlifedata.com/resource/umls/id/C1979765","p":"http://linkedlifedata.com/resource/umls/prefMetaMap"},{"p":"http://www.w3.org/1999/02/22-rdf-syntax-ns#type","o":"http://www.w3.org/2008/05/skos-xl#Label"},{"p":"http://www.w3.org/2004/02/skos/core#notation","o":"LP31479-6"},{"p":"http://www.w3.org/2004/02/skos/core#note","o":"LOINC"},{"p":"http://www.w3.org/2008/05/skos-xl#literalForm","o":"Myasthenia gravis treatment"},{"s":"http://linkedlifedata.com/resource/umls/id/C1979765","p":"http://www.w3.org/2008/05/skos-xl#prefLabel"},{"p":"http://www.w3.org/1999/02/22-rdf-syntax-ns#type","o":"http://linkedlifedata.com/resource/pubmed/Keyword"},{"p":"http://www.w3.org/2000/01/rdf-schema#label","o":"MYASTHENIA GRAVIS/x-ray treatment"},{"p":"http://www.w3.org/1999/02/22-rdf-syntax-ns#type","o":"http://www.w3.org/2008/05/skos-xl#Label"},{"p":"http://www.w3.org/2004/02/skos/core#notation","o":"254190"},{"p":"http://www.w3.org/2004/02/skos/core#note","o":"OMIM"},{"p":"http://www.w3.org/2008/05/skos-xl#literalForm","o":"MYASTHENIA, CONGENITAL, REFRACTORY TO ACETYLCHOLINESTERASE INHIBITORS"},{"s":"http://linkedlifedata.com/resource/umls/id/C1850806","p":"http://www.w3.org/2008/05/skos-xl#prefLabel"},{"s":"http://data.linkedct.org/resource/trials/NCT00424489","p":"http://data.linkedct.org/resource/linkedct/condition"},{"s":"http://data.linkedct.org/resource/trials/NCT00294658","p":"http://data.linkedct.org/resource/linkedct/condition"},{"s":"http://data.linkedct.org/resource/trials/NCT00309088","p":"http://data.linkedct.org/resource/linkedct/condition"},{"s":"http://data.linkedct.org/resource/trials/NCT00090636","p":"http://data.linkedct.org/resource/linkedct/condition"},{"s":"http://data.linkedct.org/resource/trials/NCT00285350","p":"http://data.linkedct.org/resource/linkedct/condition"},{"s":"http://data.linkedct.org/resource/trials/NCT00004682","p":"http://data.linkedct.org/resource/linkedct/condition"},{"s":"http://data.linkedct.org/resource/trials/NCT00309101","p":"http://data.linkedct.org/resource/linkedct/condition"},{"s":"http://data.linkedct.org/resource/trials/NCT00704626","p":"http://data.linkedct.org/resource/linkedct/condition"},{"s":"http://data.linkedct.org/resource/trials/NCT00306033","p":"http://data.linkedct.org/resource/linkedct/condition"},{"s":"http://data.linkedct.org/resource/trials/NCT00727194","p":"http://data.linkedct.org/resource/linkedct/condition"},{"p":"http://data.linkedct.org/resource/linkedct/condition_id","o":"8416"},{"p":"http://data.linkedct.org/resource/linkedct/condition_name","o":"Myasthenia Gravis"},{"p":"http://www.w3.org/1999/02/22-rdf-syntax-ns#type","o":"http://data.linkedct.org/resource/linkedct/condition"},{"p":"http://www.w3.org/2000/01/rdf-schema#label","o":"Condition #8416 (Myasthenia Gravis)"},{"p":"http://www.w3.org/2004/02/skos/core#exactMatch","o":"http://dbpedia.org/resource/Myasthenia_gravis"},{"p":"http://www.w3.org/2004/02/skos/core#exactMatch","o":"http://yago.org/resource/Myasthenia_gravis"}]}]}
